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Abstract 
 
Standard chemotherapies that interfere with microtubule dynamics are a chemotherapeutic 
option used for the patients with advanced malignancies that invariably relapse after targeted 
therapies. However, major efforts are needed to reduce their toxicity, optimize their efficacy, 
and reduce cancer chemoresistance to these agents. We previously identified a 
pyrrolo[2,3d]pyrimidine-based microtubule-depolymerizing agent (PP-13) that binds to the 
colchicine site of β-tubulin and exhibits anticancer properties in solid human cancer cells, 
including chemoresistant subtypes. Here, we investigated the therapeutic potential of PP-13 in 
vitro and in vivo. PP-13 induced a mitotic blockade and apoptosis in several cancer cells 
cultured in two-dimensions or three-dimensions spheroids, in conjunction with reduced cell 
proliferation. Capillary-like tube formation assays using HUVECs showed that PP-13 
displayed antiangiogenic properties. It also inhibited cancer cell motility and invasion, in in 
vitro wound-healing and transwell migration assays. Low concentration PP-13 (130 nmol.L-1) 
treatment significantly reduced the metastatic invasiveness of human cancer cells engrafts on 
chicken chorioallantoic membrane. In nude mice, 0.5 or 1 mg.kg-1 PP-13 intraperitoneally 
administered three-times a week reduced the sizes of paclitaxel-refractory orthotopic breast 
tumors, delayed the progression of metastasis, and decreased the global metastatic load 
compared to 0.5 mg.kg-1 paclitaxel or vehicle alone. PP-13 did not show any apparent early 
adverse effect in vivo. These data suggest that PP-13 is a promising alternative to standard 
chemotherapy in antimitotic drug-refractory tumors, especially through its impact on 
metastasis. 
 
Keywords: spheroids, invasion, metastasis, paclitaxel, drug-refractory tumors, 
pyrrolopyrimidine  
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1. Introduction 
 
Despite recent innovations in targeted anticancer strategies over the last decade, non-selective 
chemotherapies are still widely used for the clinical management of various patients with 
advanced malignancies [1]. Microtubules represent one of the most common targets for 
chemotherapies, as they are crucial for the maintenance of cell shape, intracellular transport, 
cell motility, and chromosome migration during cell division [2]. Taxanes and vinca-alkaloids 
are the two main classes of microtubule-targeting agents and are classically known to induce 
microtubule stabilization and depolymerization, respectively [3]. Therapeutic doses of all 
compounds from these two families lead to the alteration of the dynamic state of the 
microtubules, which ultimately induces multipolar divisions and causes cell death [4, 5]. 
Beyond their cytotoxic activity, most microtubule-binding agents display antimetastatic, 
antiangiogenic or vascular-disrupting properties, supporting their use as therapeutic agents for 
cancer treatment [6-8]. However, the troublesome side effects of microtubule inhibitors, 
particularly myelosuppression and peripheral neurotoxicity, and the emergence of 
chemoresistance, predominantly from the overexpression of efflux transporters, drastically 
limits their therapeutic outcomes [3], hence underscoring the need for alternative agents. 
We recently identified a novel pyrrolopyrimidine-based microtubule-depolymerizing agent 
(PP-13) that was effective in vitro on a wide range of human cancer cells [9]. PP-13 has no 
kinase activity, directly binds to the colchicine binding site of β-tubulin, interferes with 
microtubule organization and induces spindle multipolarity, transient mitotic cell cycle arrest 
and apoptosis [9]. Interestingly, in marked contrast to conventional microtubule-damaging 
drugs, PP-13 escapes resistance mechanisms linked to the presence of efflux pumps, which 
underlies its potential anticancer activity for multidrug-resistant cancer cells [9].  
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Based on the efficacy of PP-13 against human cancer cell proliferation and multidrug-
resistant cancer cells, the aim of the present study was to investigate the therapeutic potential 
of PP-13 against highly invasive and aggressive cancer cell lines in vitro and in vivo. The 
effects of PP-13 were analyzed in HeLa cervical cancer cells, A549 NSCLC cells and 4T1 
murine mammary cancer cells that were cultured in two-dimensions monolayers or in three-
dimensions-spheroids. The impact of PP-13 on cell migration, metastasis and angiogenesis 
was evaluated. Since no colchicine binding-site agent is currently used in clinic for cancer 
treatment, we assessed the clinical potential of PP-13 activity in comparison with paclitaxel, a 
standard anti-mitotic chemotherapy that is routinely used for the treatment of a wide range of 
solid cancers, and is considered a reference treatment for in vitro and in vivo studies of new 
microtubule-targeting agents. 
 
2. Material and Methods 
 
2.1. Materials 
 
Paclitaxel was obtained from Sigma-Aldrich (Saint-Quentin-Fallavier, France). PP-13 was 
obtained from Institut Curie (CNRS Chemical library, 2004 version), as described in [9]. All 
drugs were dissolved in sterile anhydrous dimethyl sulfoxide (DMSO, Carl Roth, Karlsruhe, 
Germany) at a 10 mmol.L-1 stock solution. Phospho-histone H3 (H3P), and active caspase-3 
antibodies were purchased from Cell Signaling Technology (Ozyme, Saint-Quentin-Les-
Yvelines, France), and conjugated Alexa Fluor 633 goat anti-rabbit antibodies were from 
Thermo Fisher Scientific (Saint-Aubin, France). 
 
2.2. Cell lines and culture 
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The human HeLa and A549 cell lines and the murine 4T1 cells were obtained from the 
American Type Culture Collection (ATCC, Manassas, VA, USA). HeLa cells expressing 
mEGFP-α-tubulin and mRFP-H2B (HeLa-EGFP/RFP) were a generous gift from Dr. D. 
Gerlich [10]. The 4T1 cells were stably transfected with a plasmid expressing the fusion 
histone H2B-RFP (provided by Dr. C. Albigès-Rizo, Institute for Advanced Biosciences, 
Grenoble, France) (4T1-RFP) or with the pGL4.50[luc2/CMV/Hygro] vector encoding the 
firefly luciferase reporter gene luc2 (Promega, Charbonnière, France) (4T1-rvLuc2) using 
JetPEI (Polyplus Transfection, Illkirch, France) according to the manufacturer’s protocol. 
Transfected cells were selected with G418 antibiotic (Invivogen Europe, Toulouse, France, 
ant-gn-5) and amplified. All cells were routinely tested for the presence of mycoplasma 
(MYCOALERT® Mycoplasma Detection Kit, Lonza, Amboise, France) and used within three 
months after thawing. A549, HeLa, and HeLa-EGFP/RFP cell lines were authenticated by 
DNA STR profiling (ATCC Cell line Authentication Service, LGC Standard SARL, 
Manassas, VA, USA). Human umbilical vein endothelial cells (HUVECs, passage two to five; 
Lonza) were cultured in complete medium of the EGM-2 BulletKit (Lonza, Amboise, 
France). 
 
2.2.1. Two-dimensions (2D) cell culture 
Cells were maintained in culture at 37°C in the appropriate medium with 10% FBS in a 5% 
CO2 humidified atmosphere, and the cell morphology was routinely checked.  
 
2.2.2. Three-dimensions (3D) cell culture 
Spheroids were generated by plating A549 (4000 cells/well), HeLa-EGFP/RFP (1000 
cells/well), or 4T1-RFP (2000 cells/well) cells into 96-well round bottom ultra-low 
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attachment (ULA) spheroid microplates (Corning, Tewksbury, MA, USA). The spheroid 
culture was performed in medium with 10% FBS in a humidified atmosphere with 5% CO2. 
Spheroid formation and growth were assessed by microscopic examination using an inverted 
microscope and by imaging the spheroids at each time point.  
 
2.3. In vitro cytotoxicity assays 
 
Cell proliferation assays were conducted in 96-well culture plates. 2D-cultured cells and 
spheroids were cultured for 24 h and 72 h, respectively, prior to treatment with PP-13 or 
paclitaxel in medium containing 10% FBS for 72 h. The cell viability was quantified using 
CELLTITER 96® AQueous One Solution cell proliferation assay (Promega, Charbonnière, 
France) in 2D cell models or by using the CELLTITER-GLO® 3D Cell Viability Assay 
(Promega, Charbonnière, France) in spheroids. The drug concentrations required to inhibit 
cell growth by 50% (IC50) were interpolated from the dose-response curves.  
 
2.4. Immunofluorescence analyses of spheroids 
 
After PP-13 treatment, the spheroids were washed, fixed overnight at 4°C in 4% 
paraformaldehyde, and then washed, frozen and cut into 7-µm sections before mounting onto 
SuperFrost UltraPlus slides (Thermo Fisher Scientific, Saint-Aubin, France). Cryosections 
were rehydrated in PBS-glycine, permeabilized for 1 h in PBS with 2% Triton X-100, washed 
in PBS-glycine, blocked in 10% goat serum and incubated overnight at 4°C with primary 
antibodies. The sections were then washed in 0.2% Tween-20/PBS and incubated for 1 h with 
conjugated secondary antibodies. Hoechst was used to counterstain the cell nuclei. 
Fluorescence microscopy was carried out using a confocal microscope (LSM 710; Carl Zeiss, 
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Jena, Germany). An objective Plan Apochromat 20×/0.8 NA in air and an objective Plan 
Apochromat 63×/1.4 NA in oil were used. The H3P and active caspase-3 expression levels in 
spheroids were counted based on color thresholding image adjustment using ImageJ software 
(NIH, Bethesda, MD, USA) and the images were blinded. The percentage of H3P was 
calculated as the number of H3P-positive cells in control and PP-13-treated spheroids (n ≥ 7 
as indicated in the figure legends, with three different sections analyzed per spheroid). The 
percentage of cleaved caspase-3 was calculated as the number of cleaved caspase-3-positive 
cells in control and treated spheroids (n ≥ 7 as indicated in the figure legends, with two or 
three different sections analyzed per spheroid). 
 
2.5. Immunoblotting 
 
Western blot analyses were performed as previously described [11] after protein extraction of 
ten pooled spheroids per condition and sonication. H3P and actin intensities were quantified 
using the Image J software and the relative densitometric area for H3P were determined 
according to actin signal in each condition. 
 
2.6. Wound-healing assay 
 
A549, 4T1-rvLuc2 and HeLa cells were seeded into 96-well plates (15000 cells/well) and 
allowed to grow for 24 h until confluence. Scratching the surface with a wound maker 
physically wounded the cell monolayers, and increasing concentrations of PP-13 or DMSO 
were added into the medium. Images of the cells invading the scratch wound were monitored 
for 12 h using the IncuCyte S3 Live-Cell analysis system (Essen Bioscience, Hertfordshire, 
UK). The relative wound density was analyzed using the IncuCyte S3 software.  
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2.7. Transwell migration and invasion assays 
 
A549, 4T1-rvLuc2 and HeLa cells were plated (75000 cells) on top of a transwell chamber 
with Matrigel (Corning, Tewksbury, MA, USA) under starvation conditions, and complete 
medium was added into the well. After 24 h of incubation with PP-13 or DMSO, cells that 
reached the bottom of the transwell were stained with methylene blue and observed by 
microscopy (AxioImager M2, Carl Zeiss, Jena, Germany). Ten images were obtained per 
condition and were blinded for quantification. Cell invasion was quantified using a fully 
connected, three-layer back-propagation neuronal network, as previously described [12]. 
Briefly, the input layer of the network was prepared to receive 12 9 12 pixel images, with 
three-color channels totaling up to 12 9 12 9 3 input neurons. A total of twenty-four neurons 
in the hidden layer were utilized. The output layer consists of two neurons corresponding to 
the two classes E (empty space between structures) and S (structure) with respect to which 
each pixel and its neighborhood were classified. A training set of ~10-20 images of each kind 
were created for training. An extended training set of ~ five hundred pictures per species was 
generated by rotating each picture by twenty-four equidistant angles, as well as rescaling to 
90, 100, and 110% of the original size. Training was performed by (on average) two thousand 
forward passes per extended training set picture, with full error back propagations. Feed-
forward and error-backward propagations employ well-known sigmoidal characteristics based 
on the logistic function. The target signals for the two output neurons were [1, 0] 
corresponding to E, and [0, 1] corresponding to S, respectively.  
 
2.8. In vitro capillary-like tube formation assay 
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A 15-well Ibidi angiogenesis microslide (Ibidi, 81506 Clinisciences, Nanterren France) was 
coated with 10 µL of Matrigel matrix (Corning) and incubated for 30 minutes at 37°C for gel 
polymerization. Twenty thousand HUVECs were seeded on top of the polymerized gel matrix 
in complete medium with increasing concentrations of PP-13 or 0.1% DMSO. The microslide 
was then placed in a 37°C heated stage in a 5% CO2 humidified atmosphere. Images were 
acquired after 6 h of incubation by a phase-contrast microscope with an Achromat 5×/0.12 
NA objective, blinded and analyzed using the automated WimTube image analysis tool 
(Wimasis GmbH, Munich, Germany). 
 
2.9. In vivo studies using chick embryo tumor model 
 
A chick embryo tumor growth and metastasis assay (InOvotion, Grenoble, France) was 
performed as previously described [9]. According to French legislation, no ethical approval is 
needed for scientific experimentations using oviparous embryos (decree number 2013–118, 
February 1, 2013; art. R-214–88). Briefly, fertilized white leghorn eggs (SFPA, Hendrix 
Genetics group, Saint Brieuc, France) were incubated at 38°C with 60% relative humidity for 
nine days. The chorioallantoic membrane (CAM) was then dropped, and a 1-cm2 window was 
cut into the eggshell above the CAM (at day nine). A total of three million A549 cells were 
added directly onto the CAM of each egg. The eggs were randomly allocated into three 
groups. Group size was determined based on the expertise of InOvotion showing that n ≥ 15 
was the minimum number of eggs to show significant effects. At day ten, when tumors began 
to be detectable, the eggs were treated every other day for ten days by adding 100 μL of either 
50 μmol.L−1 paclitaxel (n = 17), 0.13 μmol.L−1 PP-13 (n = 18), or 0.5% DMSO in PBS 
(vehicle, n = 18) dropwise onto the tumor. The concentration of paclitaxel was chosen as a 
positive control to induce significant tumor growth inhibition without toxicity for embryos. 
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The concentration of PP-13 has been arbitrarily chosen according to in vitro experiments 
(IC50) and following the expertise of InOvotion. The upper portion of the CAM was then 
removed, and the tumors were carefully cut away and weighed. In parallel, a 1-cm2 portion of 
the lower CAM was collected, genomic DNA was extracted, and qPCR analysis was 
performed by using primers specific for genomic human Alu/repetitive sequences [9] to 
evaluate the number of A549 cells. Finally, scoring the number of dead embryos and looking 
for morphological or functional abnormalities in the surviving embryos was carried out to 
evaluate the toxicity of the treatment. 
 
2.10. In vivo studies using mice tumor model 
 
All animal studies were performed in accordance with the European Economic Community 
guidelines and the “Principles of Laboratory Animal Care” (NIH publication N 86-23 revised 
1985) and were approved by the institutional guidelines and the European Community (EU 
Directive 2010/63/EU) for the use of experimental animals (authorization for the experiment: 
APAFIS#8854-2017031314338357 v1). 
 
Six-week-old female NMRI nude mice (Janvier Labs, Le Genest-Saint Isle, France) were 
anesthetized using 4% isoflurane/air for anesthesia induction and 1.5% thereafter, and 
luciferase-modified mouse 4T1 cancer cells (4T1-rvLuc2 cells, 20000 cells per 50 µL) were 
injected into the mammary fat pad. The mice were immediately randomly divided into four 
groups of eight mice, receiving vehicle (0.9% NaCl, 1% DMSO, 30% PEG, 1% Tween-80, 
referred to as control), 0.5 mg.kg-1 paclitaxel, 0.5 mg.kg-1 PP-13, or 1 mg.kg-1 PP-13. Group 
size was determined based on our expertise showing that n ≥ 8 per group was the minimum 
number of mice to show significant effects on metastases. Based on the results obtained on 
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chick embryo tumor model showing the effect of PP-13 at very low dose, two low 
concentrations of PP-13 were chosen (0.5 and 1 mg.kg-1). Similar low concentration (0.5 
mg.kg-1) was chosen for paclitaxel to compared this standard chemotherapy with PP-13, and 
based on preliminary experiments showing sub-therapeutic effect of 0.5 mg/kg-1 paclitaxel on 
tumor and metastases growth (data not shown). Intraperitoneal administration of 200 µL of 
treatment was performed three times per week for five weeks. The mice were examined daily 
for behavior and morbi-mortality and were weighed three times per week. The primary tumor 
growth was monitored three times per week using a caliper, and the tumor volume was 
calculated as follows [13]: tumor volume = length x width  x 0.4. The thoracic metastasis 
growth was followed once per week by in vivo bioluminescence imaging (IVIS KINETIC, 
Perkin Elmer, Waltham, MA, USA) 5 min after the intraperitoneal injection of 150 mg.kg-1 of 
luciferin (Promega, E1605), as previously described [14]. Twenty-two days after 4T1-rvLuc2 
cell implantation, 0.1 mg.kg-1 buprenorphine was injected subcutaneously for analgesia and 
the primary breast tumors were excised under general anesthesia. The mice were carefully 
observed during the day following the surgery. After five weeks, the mice were sacrificed and 
blood samples were collected by cardiac puncture using a heparinized syringe. The lungs, 
axillary and brachial lymph nodes, kidney and liver were harvested for further imaging and/or 
analyses.  
 
2.11. Ex vivo studies of mice tissue samples 
 
Blood samples were evaluated for hematological parameters with a medical automated 
hematology analyzer (Micros-60, Horiba ABX, Montpellier, France), and biochemical 
analyses were performed by the Charles Rivers Laboratory (Massachusetts, USA). Bone 
marrow was obtained after having carefully sectioned mice femurs at each joint and flushing 
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the bone cavity with PBS. Cells from the plasma and bone marrow samples were washed in 
PBS, cytospun (Cytospin 4, Fisher Scientific, Illkirch, France) and stained with May-
Grunwald-Giemsa solution (MGG) with the automated XE-5000 Instrument (Sysmex, Roissy, 
France). Global cell abundance evaluation and megakaryocyte and leukocyte counting were 
then performed for both samples by an experienced hematologist. 
Tumor tissues were frozen in OCT-embedding medium (VWR international, Fontenay-sous-
Bois, France) and cut into 7 μm thick sections using a cryomicrotome for 
immunohistochemical analyses. Immunohistochemical examinations were performed after 
fixation with 4% paraformaldehyde and staining with anti-CD31 antibody (Pharmingen, BD 
Biosciences, Le Pont de Claix, France), using an AxioImager M2 microscope (Carl Zeiss, 
Jena, Germany). Segmentation of tissues was performed using a fully connected, three-layer 
back-propagation neuronal network, as previously described [12]. 
 
2.12. Statistical analyses 
 
All analyses were performed using the GraphPad Prism software (GraphPad Software Inc., 
San Diego, California, USA). Statistical comparisons between two groups or more were 
conducted with Mann-Whitney test, Kruskal-Wallis test, or Friedman test with Dunn’s 
multiple comparisons post hoc test. Statistical comparisons between mice groups among time 
were determined by two-way ANOVA with Bonferroni’s post hoc test. Statistical significance 
was defined for p values ≤0.05.  
 
3. Results 
 
3.1. PP-13 treatment decreases cancer cell proliferation in vitro 
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To investigate the therapeutic effect of PP-13, we chose three cell lines displaying high levels 
of proliferation, migration and invasiveness: the human HeLa cervical cell line and its 
derivative subclone expressing mEGFP-D-tubulin and mRFP-H2B (HeLa-EGFP/RFP), the 
human A549 lung cancer cell line, and the mouse 4T1 mammary cancer cells expressing 
mRFP-H2B (4T1-RFP) or luciferase (4T1-rvLuc2). We first analyzed the toxicity of PP-13 in 
these cell lines cultured in monolayers or in 3D-spheroids. PP-13 had a significant effect on 
the proliferation of these cell lines, strongly reducing their viability (Fig. 1A). The IC50 values 
of PP-13 (50% growth inhibition) were relatively similar for the three cell lines cultured in 
monolayers (Table 1) [9]. These IC50 values did not vary significantly when the cells were 
grown in spheroids, except for A549 (Table 1 and Fig. 1A and 1B). Indeed, the A549 
spheroids appeared to strongly resist PP-13 treatment compared to A549 cells in the 
monolayer cell culture. Similar effects were observed in these cell lines with the reference 
antimitotic chemotherapy paclitaxel (Table 1 and Fig. 1). We have shown that paclitaxel has a 
reducing effect on 4T1 cell viability in 2D culture compared to A549 (~five-fold lower) and 
HeLa (~ten-fold lower) cells, thus reflecting the resistance of 4T1 cells to paclitaxel. In 
addition, although 4T1-RFP spheroids were surprisingly more sensitive to low doses of 
paclitaxel than monolayer 4T1-RFP cells, high concentrations of paclitaxel failed to inhibit 
more than 50% of the cell proliferation of both A549 and 4T1 spheroids. Thus, PP-13 affected 
the proliferation of invasive cells in vitro, including those that are resistant to paclitaxel. 
 
3.2. PP-13 treatment induces mitotic blockade in cancer cell spheroids 
 
We previously demonstrated that PP-13 induced a transient mitotic blockade by interfering 
with mitotic spindle organization and microtubule dynamics in monolayer cell cultures [9]. 
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Here, we analyzed the effect of PP-13 on mitosis in spheroids. The cell viability of HeLa-
EGFP/RFP spheroids was not impacted by a short 24 h treatment of 200 nmol.L-1 PP-13 (data 
not shown). Alpha-tubulin and phosphorylated histone H3 (H3P), a marker of late G2/M cell 
cycle phase, were analyzed by confocal microscopy on HeLa-EGFP/RFP spheroid sections 
(Fig. 2A). We observed that PP-13 led to mitotic defects, including multiple misoriented and 
shortened mitotic spindles (green arrows) associated with chromosomes miscongression (blue 
arrows). In addition, we showed a significant increase in the level of H3P after 24 h of PP-13 
treatment, reflecting the strong accumulation of cells in mitosis in the HeLa-EGFP/RFP 
spheroids (Fig. 2C). As expected, paclitaxel also enhanced the level of H3P in HeLa-
EGFP/RFP spheroids but to a lower extent than PP-13 and with an effect mainly on the cells 
at the periphery of the spheroids (Fig. 2B and 2C). Accumulation of H3P in response to PP-13 
treatment was also increased in A549 spheroids compared to untreated control (Fig. 2C), and 
was confirmed by western blot of the three spheroid types (Fig. 2D). Finally, after 72 h of PP-
13 treatment, the HeLa-EGFP/RFP spheroids showed a significant increase in cleaved 
caspase-3 (Fig. 2E and 2F). Therefore, in spheroid cultures, PP-13 induced mitotic spindle 
disorganization, mitotic blockade, inhibition of cell growth and apoptosis. 
 
3.3. PP-13 inhibits angiogenesis in vitro 
 
Because most of the microtubule-targeting agents also exhibit antiangiogenic properties [3, 6, 
15, 16], we investigated the effects of PP-13 on capillary-like structure formation in vitro 
using HUVECs plated on a Matrigel basement membrane. In control conditions, endothelial 
cells aligned and formed organized networks of capillary-like structures after 6 h (Fig. 3A). 
PP-13 treatment reduced the total number of branching points, the number of loops, the length 
of the tubes, and the total cell-covered area compared to the control (Fig. 3B). Altogether, PP-
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13 altered the ability of HUVECs to form tube-like structures. The concentrations of PP-13 
that were used had limited impact on HUVEC proliferation (Fig. 3C). Hence, this suggested 
that PP-13 displayed antiangiogenic properties in vitro. 
 
3.4. PP-13 inhibits the migration of cancer cells in vitro 
 
Given the essential role of microtubules in cell motility, we investigated whether the PP-13 
tubulin inhibitor impacted HeLa, A549, and 4T1-rvLuc2 cell migration and invasiveness in 
vitro. The impact of PP-13 on the motility of cells was examined using an in vitro wound-
healing assay. We observed that PP-13 significantly reduced the motility of the three cell lines 
in a dose-dependent manner, and as paclitaxel (Fig. 4A and 4B). The effect of PP-13 on 
invasive migration was assessed with Matrigel in transwell chambers. PP-13 exerted a strong 
inhibitory effect on the invasion of the three cell lines (Fig. 4C and 4D). Paclitaxel also 
inhibited the invasion of these cells. These results indicated that PP-13 is able to slow down 
cell motility and invasion in vitro. 
 
3.5. PP-13 inhibits the migration of cancer cells in vivo 
 
We previously showed that PP-13 reduces tumor growth and metastatic invasion in vivo by 
using H358 NSCLC cells engrafted onto chicken chorioallantoic membranes (CAMs) [9]. 
Here, we used A549 NSCLC cells engrafted onto the CAMs to evaluate the efficacy of PP-13 
on the migration of invasive cancer cells. The tumors were treated every other day with 
vehicle (control), PP-13, or paclitaxel (Fig. 5A). At the end of the experiment, the tumors 
were recovered from the upper CAMs and weighed. We used a very low concentration of PP-
13 (0.13 μmol.L-1) compared to the > 10 µmol.L-1 PP-13 IC50 in the A549 spheroid cell 
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culture (Table 1), which did not inhibit A549 tumor growth (Fig. 5B). Analysis of the 
presence of A549 cells at the lower CAM by qPCR, allowing for the accurate detection of 
tumor cell dissemination, showed that this low dose of PP-13 significantly reduced the 
metastatic ability of A549 cells compared to the control (Fig. 5C). Paclitaxel was used as a 
positive control at a concentration known to inhibit A549 tumor growth and metastatic 
dissemination without inducing significant toxicity (Fig. 5B and 5C) [9]. These results 
suggested that PP-13 inhibited invasion in vivo. Furthermore, treatment with PP-13 did not 
significantly increase the mortality (two embryos died in the control group, and one embryo 
died in both paclitaxel and PP-13-treated groups) or abnormalities (no abnormality observed 
on surviving embryos for the different experimental groups) on chicken embryos, indicating 
that it was well tolerated. 
 
3.6. PP-13 impairs tumor progression and metastasis in an allogeneic breast cancer 
model 
 
To further evaluate the effect of PP-13 on tumor growth and metastasis formation, we used 
the allogeneic model of 4T1-rvLuc2 cell engraftment in the mammary fat pads of mice. We 
chose this model because once engrafted orthotopically in the mammary gland, 4T1-rvLuc2 
mouse cancer cells metastasize to multiple distant sites (lymph nodes, lungs, liver, bone, 
brain), thus mimicking human breast cancers [17]. As soon as the 4T1-rvLuc2 cells were 
inoculated, the mice were randomly divided into four groups: one control group, one group 
treated with paclitaxel (0.5 mg.kg-1) and two groups treated with PP-13 (0.5 and 1 mg.kg-1) 
(Fig. 5D). The low concentrations of PP-13 were chosen based on the results obtained on 
chick embryo tumor model showing an inhibitory effect of PP-13 at very low dose, and were 
compared to the same concentration of the standard chemotherapy paclitaxel. Intraperitoneal 
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injections of each treatment were performed three times per week. The tumor progression was 
not affected at early time points, but the final tumor volumes were significantly lower after 
three weeks for the two groups treated with PP-13 in this rapidly progressing breast cancer 
model (Fig. 5E). The potential antiangiogenic activity of PP-13 in vivo was assessed sections 
performed on primary tumors stained with an anti-CD31 antibody. The microvessel density 
was counted and showed no significant difference between the treatments at the 
concentrations used and at this time-point (Fig. 5F). No significant difference between the 
treatments was observed in Ki67 immunostaining either (data not shown). 
 
In vivo bioluminescence imaging was used to follow the development of thoracic metastases 
before and after primary tumor resection (Fig. 5D). Paclitaxel had no effect on the 
bioluminescence signal compared to the control treatment and even slightly enhanced it at day 
28 (Fig. 6A and 6B). In contrast, the signal of thoracic metastasis was reduced with PP-13 
treatment. Of note, both PP-13 and paclitaxel treatment reduced the number of mice with 
thoracic metastases compared to the control treatment from 2 weeks of treatment (Fig. 
6C)(Table 2). These results were confirmed by measuring bioluminescence in the lungs ex 
vivo at the end of the experiment (day 35) (Fig. 6C). This showed a non-significant 66% 
reduction in the lung metastasis signal in mice treated with 1 mg.kg-1 PP-13 compared to 
control mice (Fig. 6D). In addition, ex vivo, the axillary and brachial lymph nodes showed a 
significant decrease in signal in both of the PP-13-treated groups compared to the control and 
paclitaxel-treated groups (Fig. 7A and 7B). The percentage of mice with axillary and brachial 
lymph node metastases was reduced in a dose-dependent manner in the PP-13-treated groups 
compared to the control and paclitaxel-treated groups (Fig. 7C)(Table 2), as was the number 
of metastatic axillary and brachial lymph nodes (Fig. 7A). Taken together, these results 
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showed that PP-13 decreased tumor and metastatic growth dissemination in this breast cancer 
model. 
 
3.7. PP-13 shows no adverse side effects in vivo 
 
We assessed the toxicity of PP-13 and paclitaxel in vivo. There was no body-weight loss in 
the control and PP-13-treated mice over the course of the experiment, while mice exposed to 
paclitaxel displayed a significant decrease in body weight at the end of the experiment (Fig. 
7E) (Table 3). In addition, one of the eight mice in each of the paclitaxel and control groups 
died before the end of the experiment probably because of tumor progression, while all PP-
13-treated mice survived suggesting that PP-13 may control tumor progression. 
 
We paid particular attention to some of the side effects described for conventional spindle 
poisons in patients. Serum biochemical analysis showed significant decreases in phosphorus, 
creatinine, and glucose in paclitaxel-treated mice compared to the control group (Table 4). No 
significant changes in serum biochemical values were reported in PP-13-treated mice, except 
a small and isolated decrease in blood urea nitrogen that did not reflect any renal toxicity in 
this context. In addition, macroscopic analyses of the organs of the treated mice did not show 
evidence of damage (data not shown). Hematological analysis of the blood and bone marrow 
cells from mice treated with PP-13 did not reveal any apparent signs of myelosuppression or 
other hematological abnormalities compared to the control (Table 5). In contrast, paclitaxel 
treatment led to a significant reduction in the white blood cell (WBC) count and a slight 
increase in the mean corpuscular hemoglobin concentration (MCHC). 
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Overall, these data suggest that PP-13 displays a favorable safety profile, as it slows both 
tumor and metastasis progression and is well tolerated at these doses compared to the control 
and paclitaxel. 
 
4. Discussion 
 
The new pyrrolo[2,3d]pyrimidine-based colchicine-binding site agent PP-13 showed 
promising anticancer properties in vitro [9]. In this study, we explored the therapeutic 
potential of PP-13, particularly in conditions leading to invasive cancer cell phenotype, and 
compared the effects of PP-13 with those of paclitaxel, a widely used tubulin-targeting agent 
in solid tumors. We showed that PP-13 inhibited proliferation, migration and angiogenesis in 
vitro, which may potentiate its antineoplastic activity, and reduced metastatic progression 
dissemination in paclitaxel-resistant tumors in vivo, with no detectable adverse side effects. 
 
We confirmed the in vitro antitumor effects of PP-13 in spheroids. The PP-13-treated 
spheroids showed enhanced H3P levels associated with defects in mitotic spindle organization 
and chromosome congression, thus confirming in three-dimensions models that PP-13 
induced an early mitotic blockade. Late caspase-3-dependent apoptotic mechanisms 
contributed to the decrease in spheroid growth, as was previously described in two-
dimensions cell cultures [9]. Spheroids are currently considered to be a more suitable model 
than monolayer cell cultures because they better mimic the in vivo three-dimensions tumor 
environment and cell-cell and cell-extracellular matrix interactions [18-20]. Large spheroids 
(≥ 300 µm diameter), such as those generated in our experiments, display a hypoxic core 
resulting from chemical gradients of oxygen and nutrients that are correlated with 
chemoresistance, as reported in developing tumors [21]. We observed differences in the IC50 
values of PP-13 between monolayer cell culture and spheroids. In particular, A549 cells were 
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resistant to PP-13 when cultured in spheroids, in contrast to monolayer cell culture, 
suggesting that the effect of PP-13 observed on two-dimensions-culture cell proliferation is 
reduced in spheroids. The presence of various environmental factors affecting the tumor 
development (e.g., cell–cell adhesion, cell-cycle distribution, local pH, extracellular matrix) 
[20] could explain the lower sensitivity of spheroid cancer cells to drugs compared to two-
dimensions cell cultures, as was also observed in different in vivo tumor models [22-24]. The 
physicochemical properties of PP-13 could also be responsible for the lower sensitivity in 
three-dimensions cell culture. 
Despite opposite mechanisms of action (microtubule stabilization or depolymerization) [3], 
both PP-13 and paclitaxel lead to the disruption of the microtubule organization and the 
induction of cancer cell cycle arrest and apoptosis. 
Angiogenesis and cancer cell migration are attractive therapeutic targets [25]. The widely 
used capillary-like tube formation assay aids in studying the effects of new molecules on 
many steps of neoangiogenesis, including endothelial cell adhesion, migration, and tubule 
formation [26]. With this approach, we showed that PP-13 interfered with the tubule assembly 
in vitro by decreasing both the number of loops and branch nodes, the total length of the formed 
tubes and the cell-covered area. Using in vivo 4T1 primary breast tumor models, we did not 
observe any impact of PP-13 on microvessel density, suggesting that such PP-13 
concentrations were inadequate to induce antiangiogenic activities and/or that the study time 
was not suitable to inhibit endothelial cells in vivo in this rapidly progressing breast cancer 
orthotopic model.  
 
PP-13 inhibited cell motility and invasion both in vitro and in vivo. In vitro, we found that 
PP-13 inhibited cancer cell migration in the three metastatic tumor cell types. In addition, PP-
13 reduced metastatic invasion in H358 [9] and A549 NSCLC cells engrafted onto chicken 
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CAMs at concentrations that did not inhibit cell proliferation in A549 spheroids. Accordingly, 
PP-13 did not inhibit A549 tumor growth in chicken CAMs. This confirmed the lower effect 
of PP-13 on cell proliferation in spheroids and in vivo compared to monolayer cell culture. 
The orthotopic mouse model of breast cancer that was used is clinically relevant to predict the 
influence of the organ microenvironment on tumor cell behavior and to study the cancer cell 
invasion and metastatic growth [27]. Although PP-13 did not inhibit in vivo tumor cell 
migration and metastasis seeding at the concentrations used, we observed that the growth of 
the metastases was delayed, and their size remained small in both lungs and lymph nodes 
when the cells migrated from the primary tumor. Although PP-13 had both antiproliferative 
and antimigration effects in vitro, the in vivo experiments indicated that the effect of the drug 
on the inhibition of invasion was stronger than its antiproliferative effects. 
 
Overall, our data indicate that PP-13 could be a potent agent to decrease the growth of both 
primary tumors and their metastases, especially for triple-negative breast cancers (TNBC), 
which account for nearly 15% of breast cancers and have poor therapeutic options and 
prognoses [28]. The 4T1 allogeneic transplant mouse model mimics TNBC in humans and is 
associated with a high propensity to metastasize, primarily in the lymph nodes and lungs. The 
therapeutic arsenal for TNBC mainly consists of anthracyclines and taxane-based 
chemotherapies; however, the emergence of resistance and frequent tumor recurrence support 
the need to identify alternative drugs for the management of refractory tumors. The 4T1 
model thus represents an interesting approach to screen new molecules for TNBC therapy, 
especially since it spontaneously metastasizes in the same regions as in TNBC and easily 
develops resistance to chemotherapies classically used in TNBC [29, 30]. Compared to 
paclitaxel, which was used as a reference treatment to reduce metastasis while limiting the 
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adverse effects, PP-13 moderately inhibited primary tumor growth and delayed metastatic 
growth.  
 
PP-13 treatment did not show any sign of toxicity compared to the controls; there was notably 
an absence of myelosuppression, which is classically observed with conventional antimitotic 
drug treatments or colchicine binding-site agents [3]. At the same dose, paclitaxel led to a 
significant decrease in white blood cell count, as has been previously reported [31], as well as 
a slight reduction in plasma glycaemia, phosphorus and creatinine and an increase in MCHC. 
Further investigations with higher concentrations of PP-13 will be needed to establish the 
maximal antitumor effect of PP-13, and the therapeutic index of the molecule, and long-term 
survival. In addition, PP-13 has no kinase activity [9] but may target other molecule than 
tubulin, that remains to determine. 
 
5. Conclusions 
In summary, PP-13 significantly reduced the cancer cell migration and neoangiogenesis 
processes in vitro. PP-13 also led to a reduction in both tumor growth and metastatic 
progression dissemination in vivo in a mouse orthotopic TNBC model without any significant 
toxicity. These findings suggest that PP-13 should be an efficient anticancer therapy and an 
alternative option to conventional spindle poisons such as taxanes or vinca-alkaloids. 
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Figure legends 
 
Table 1: Sensitivity of cancer cell lines to PP-13 and paclitaxel. The drug concentrations 
required to inhibit cell growth by 50% (IC50) at 72h in HeLa cells, HeLa mEGFP-α-tubulin and 
mRFP-H2B cells (HeLa-EGFP/RFP), A549 cells, 4T1 mRFP-H2B cells (4T1-RFP) and 4T1-rvLuc2 
cells cultured in 2D-monolayer (2D) or spheroids. Data represent the mean ± SD of three independent 
experiments, each performed in triplicate. 
 
Table 2: PP-13 decreased the number of mice with thoracic and lymph node metastases. 
Mice with 4T1-rvLuc2 tumors were treated with vehicle (control), paclitaxel 0.5 mg.kg-1, or 
PP-13 (0.5 and 1 mg.kg-1) (see Fig. 5D). Number and percentages of mice with thoracic 
metastases at day 14, and with invaded axillary and brachial lymph nodes at day 35 are shown 
in each group. 
 
Table 3: Mice body-weight. Mice with 4T1-rvLuc2 tumors were treated with vehicle 
(control), paclitaxel 0.5 mg.kg-1, or PP-13 (0.5 and 1 mg.kg-1) (see Fig. 5D). Mice body-
weight is expressed as mean ± SEM (n=8, except in paclitaxel-treated group at day 35, n=7), 
and as percentage of initial body-weight (day 0). * p <0.05; two-way ANOVA with 
Bonferroni post-test (day 35 compared to day 28). 
 
Table 4: Biochemical analyses of mice. Plasma biochemical values of mice after control, 
paclitaxel or PP-13 treatments were assessed. Data represent the mean ± SD of 6 mice per 
group. Data were analyzed using Mann-Whitney U-test. * Significant as compared to control 
group. 
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Table 5: Hematological and bone marrows analyses of mice. Complete blood count and 
white blood cells count and evaluation of the global cell abundance and megakaryocyte and 
leukocyte counts in the bone marrow, from mice treated with control, paclitaxel, or PP-13. 
Data represent the mean ± SD of 8 mice per group. # from score 1 (low abundance) to score 4 
(high abundance). Data were analyzed using one-way analysis of variance. NS: not 
significant. 
 
Figure 1: Viability of cancer cells treated with PP-13 or paclitaxel. 
A. A549, 4T1 mRFP-H2B (4T1-RFP), and HeLa mEGFP-α-tubulin mRFP-H2B (HeLa-
EGFP/RFP) were cultured in two-dimensions (2D) or in spheroids, and treated for 72 h with 
increasing concentrations of PP-13 (left) or paclitaxel (right), and the cell viability was 
assessed. Data represent the mean ± SD from three independent experiments, each performed 
in triplicate. B. Representative images of treated spheroids are shown. Bars: 100 µm. 
 
Figure 2: Effects of PP-13 on cancer cell spheroids. 
HeLa mEGFP-D-tubulin mRFP-H2B (HeLa-EGFP/RFP) spheroids were treated with vehicle 
(control), 200 nmol.L-1 PP-13, or 15 nmol.L-1 paclitaxel for 24 h (A-D) or for 72 h (E-F). 
A549 spheroids were treated for 24 h with vehicle (control) or 10 µmol.L-1 PP-13 (C-D). 4T1 
mRFP-H2B (4T1-RFP) spheroids were treated for 24 h with vehicle (control) or 200 nmol.L-1 
PP-13 (D). A. Representative confocal microscopy images of microtubules (α-tubulin-EGFP) 
and phosphorylated histone H3 (H3P, a marker of late G2/M cell cycle phase) 
immunodetection in spheroid sections treated with vehicle (control) or PP-13. In purple: H3P, 
in green: α-tubulin, in red: H2B-RFP, in blue: Hoechst-stained nuclei. The green and blue 
arrows indicate multipolar mitotic spindles and miscongressed chromosomes, respectively. 
Scale bars: 50 µm (20x magnification) and 10 µm (63x magnification). B. Representative 
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confocal microscopy images of H3P analyzed by immunofluorescence on spheroids sections 
treated with vehicle (control), or paclitaxel. In pink: H3P, in blue: Hoechst-stained nuclei. 
Scale bars: 50 µm. C. The percentage of H3P was calculated as the number of H3P-positive 
cells in control (n = 7, HeLa-EGFP/RFP; n=11, A549), PP-13 (n = 13, HeLa-EGFP/RFP; 
n=11, A549), or paclitaxel (n = 9, HeLa-EGFP/RFP) spheroids, with two or three sections per 
spheroid. Data are expressed as the mean ± SD. *** p < 0.0001 between control and treated 
conditions; Mann-Whitney U-test. D. Western blot analysis of H3P in A549, 4T1-RFP, or 
HeLa-EGFP/RFP pooled spheroids (n = 10 spheroids in each condition). Actin was used as a 
loading control. Values indicate relative H3P/actin ratio. E. Representative confocal 
microscopy images of cleaved caspase-3 immunodetection in spheroid sections. In purple: 
cleaved caspase-3, in green: α-tubulin, in red: H2B-RFP, in blue: Hoechst-stained nuclei. 
Scale bars: 50 µm. F. Quantification of cleaved caspase-3 in spheroids (control, n = 9 
spheroids; PP-13, n = 7 spheroids; with two or three sections per spheroids). Data are 
expressed as the mean ± SD. *** p < 0.0001 between control and treated conditions; Mann-
Whitney U-test.  
 
Figure 3: In vitro effects of PP-13 on angiogenesis.  
HUVECs were treated with vehicle (control) or increasing concentrations of PP-13, as 
indicated, for 6 h. A. Capillary-like tube formation assay: representative images of the 
HUVEC capillary-like tube formation in each condition. Bar: 200 µm. B. Quantification of 
the tube length, the cell-covered area, the number of loops and the number of branching 
points. Data are expressed as the mean ± SD and as the percentages of vehicle condition to 
control the seeding variations between the experiments (n = 5). * p < 0.05; ** p < 0.01; *** p 
< 0.001 between control and treated conditions; Kruskal-Wallis test with Dunn’s multiple 
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comparisons post hoc test. C. HUVEC cell viability was assessed. Data represent the mean ± 
SD (n ≥ 3). 
 
Figure 4: In vitro effects of PP-13 on cancer cell migration and invasion.  
A-B. Wound-healing assay in A549, HeLa, and 4T1-rvLuc2 cells treated with vehicle 
(control) or increasing concentrations of PP-13 or paclitaxel for 12 h. A. Representative 
images from wound-healing assay experiment at 0 h and 12 h. Cells were treated with vehicle 
(control), 1 µmol.L-1 (A549 and HeLa) or 0.5 µmol.L-1 (4T1-rvLuc2) PP-13, 20 nmol.L-1 
(HeLa) or 50 nmol.L-1 (A549) or 200 nmol.L-1 (4T1-rvLuc2) paclitaxel. The white lane 
delineates the edges of the wound. B. Relative wound density over time in cells treated as 
indicated. The relative wound density at 0 h is arbitrarily set to 0%. Data are expressed as the 
mean ± SD. Experiments were performed at least five times in triplicate. * p < 0.05; ** p < 
0.01; *** p < 0.001 compared to control or treated conditions as indicated; Friedman test with 
Dunn’s multiple comparisons post hoc test. C-D. Matrigel invasion assay of A549, 4T1-
rvLuc2 and HeLa cells treated treated with vehicle (control), 200 nmol.L-1 (4T1-rvLuc2) or 
500 nmol.L-1 (A549, HeLa) PP-13, or 20 nmol.L-1 (HeLa), 40 nmol.L-1 (A549), or 150 
nmol.L-1 (4T1-rvLuc2) paclitaxel for 24 h. C. Representative images from methylen-blue 
stained cells treated with vehicle (control), PP-13, or paclitaxel. The red squares show the 
quantified cells. D. Quantification of invasion of cells treated with vehicle (control), PP-13, or 
paclitaxel. Cells were counted in ten fields per condition and in three independent 
experiments. Data are expressed as the mean ± SD and as the percentages of vehicle condition 
to control variations between the experiments. * p < 0.05; ** p < 0.01  between control and 
treated conditions; Mann-Whitney U-test. 
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Figure 5: Effects of PP-13 in vivo.  
A. Schematic representation of the in ovo assay principle. A549 cells were engrafted onto 
chick embryo chorioallantoic membranes (CAMs) at E9, were randomized into three groups, 
and treatments with 0.5% DMSO (control, n = 18), 50 µmol.L-1 paclitaxel (positive control of 
tumor growth inhibition, n = 17), or 0.13 µmol.L-1 PP-13 (low dose, n = 18) were 
administered every other day for 10 days. B. Tumors were excised and weighted at the end of 
the treatments. The histogram represents the effect of treatments on A549 tumor weight 
(means ± SEM, n = 16). *** p < 0.001 compared to control; Kruskal-Wallis test. C. The 
presence of A549 cells in the lower CAM at the end of the experiment was evaluated by 
qPCR in ten random embryos per group. The histogram represents the effect of treatments on 
A549 metastases in the lower CAM (means ± SEM, n = 10). The relative amount of 
metastases in the lower CAM in the control group is arbitrarily set to one to control 
interindividual variations. *** p < 0.001 compared to control; Kruskal-Wallis test. 
D. Schematic representation of orthotopic breast tumors and metastatic growth and of the 
treatment plan. The mice were inoculated with 4T1-rvLuc2 cells and randomized into four 
groups of eight mice. Vehicle (control), 0.5 mg.kg-1 paclitaxel, or 0.5 or 1 mg.kg-1 PP-13 were 
administered intraperitoneally three times a week. Thoracic bioluminescence imaging was 
performed once a week for five weeks. After three weeks, the primary tumors were resected. 
E. Primary tumor volume. Data represent the mean ± SEM in each group (n = 8). *** p < 
0.001 compared to control group; two-way ANOVA with Bonferroni post hoc test. F. 
Histogram shows the CD31 positive staining quantification on frozen 4T1-tumor sections, 
expressed as the mean ± SD. The CD31 levels were determined after counting positive 
stained blood vessel area as described in methods, in three sections per tumor and in three 
tumors per group. 
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Figure 6: Effects of PP-13 on thoracic metastases in orthotopic breast tumor model. 
Mice with 4T1-rvLuc2 tumors were treated with vehicle (control), paclitaxel 0.5 mg.kg-1, or 
PP-13 (0.5 and 1 mg.kg-1), 3 times a week (see Fig. 5D). A. In vivo bioluminescence images 
of the thoracic metastases (ventral view) in one representative mouse per group at day twenty-
eight. B. Overtime quantification of in vivo bioluminescence signal in thoracic areas over the 
duration of the experiment (ventral and dorsal views). Data are expressed as the mean ± SEM 
(n = 8). * p < 0.05; **** p < 0.0001 compared to control or to paclitaxel-treated groups; two-
way ANOVA with Bonferroni post hoc test. C. Percentage of mice with and without thoracic 
metastases at day 14 in each group (n = 8). Numbers indicate the reduction in mice with lung 
metastases in each treatment group, compared to control group. D. Ex vivo bioluminescence 
images of lungs at the end of the experiment (day 35). (n = 8, except in paclitaxel-treated 
group, n = 7). E D. Ex vivo bioluminescence signal in each lung at the end of the experiment 
(day 35). Bars: mean bioluminescence signal (n = 8, except in paclitaxel-treated group, n = 7). 
Number indicates the reduction (%) in mean bioluminescence signal in 1 mg.kg-1 PP-13-
treated group, compared to control group.  
 
Figure 7: Effects of PP-13 on lymph node metastases. 
Axillary and brachial lymph nodes were collected at the end of the experiment (day thirty-
five) in 4T1-rvLuc2 mice treated as indicated. A. Ex vivo bioluminescence images of lymph 
nodes. RA, right axillary lymph node; LA, left axillary lymph node; RB, right brachial lymph 
node; LB, left brachial lymph node. Each line shows the lymph nodes of one mouse (n = 8, 
except in paclitaxel-treated group, n = 7). Numbers indicates the invaded lymph nodes and 
their percentages in each group. B. Ex vivo bioluminescence signal in each lymph node. Bars: 
median bioluminescence signal (n = 32 lymph nodes/group, 8 mice/group except in 
paclitaxel-treated group: 7 mice, 28 lymph nodes). * p < 0.05; *** p < 0.001; **** p < 0.0001 
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compared to control or treated groups; Kruskal-Wallis with Dunn’s multiple comparisons post 
hoc test. ns, not significant. C. Percentage of mice with and without invaded lymph nodes in 
each group (n = 8,  except in paclitaxel-treated group, n = 7). Numbers indicate the reduction 
in mice with lymph node metastases in each treatment group compared to the control group. 
D. Percentage of lymph nodes with and without metastases in each group (n = 32, except in 
paclitaxel-treated group, n = 28). Numbers indicate the reduction in invaded lymph nodes in 
each treatment group compared to the control group. E. Mice body-weight (means ± SEM, 
n=8 except in paclitaxel-treated group at day 35, n = 7). * p<0.05; two-way ANOVA with 
Bonferroni post-tests; NS not significant. 
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Abstract 
 
Standard chemotherapies that interfere with microtubule dynamics are a chemotherapeutic 
option used for the patients with advanced malignancies that invariably relapse after targeted 
therapies. However, major efforts are needed to reduce their toxicity, optimize their efficacy, 
and reduce cancer chemoresistance to these agents. We previously identified a 
pyrrolo[2,3d]pyrimidine-based microtubule-depolymerizing agent (PP-13) that binds to the 
colchicine site of β-tubulin and exhibits anticancer properties in solid human cancer cells, 
including chemoresistant subtypes. Here, we investigated the therapeutic potential of PP-13 in 
vitro and in vivo. PP-13 induced a mitotic blockade and apoptosis in several cancer cells 
cultured in two-dimensions or three-dimensions spheroids, in conjunction with reduced cell 
proliferation. Capillary-like tube formation assays using HUVECs showed that PP-13 
displayed antiangiogenic properties. It also inhibited cancer cell motility and invasion, in in 
vitro wound-healing and transwell migration assays. Low concentration PP-13 (130 nmol.L-1) 
treatment significantly reduced the metastatic invasiveness of human cancer cells engrafts on 
chicken chorioallantoic membrane. In nude mice, 0.5 or 1 mg.kg-1 PP-13 intraperitoneally 
administered three-times a week reduced the sizes of paclitaxel-refractory orthotopic breast 
tumors, delayed the progression of metastasis, and decreased the global metastatic load 
compared to 0.5 mg.kg-1 paclitaxel or vehicle alone. PP-13 did not show any apparent early 
adverse effect in vivo. These data suggest that PP-13 is a promising alternative to standard 
chemotherapy in antimitotic drug-refractory tumors, especially through its impact on 
metastasis. 
 
Keywords: spheroids, invasion, metastasis, paclitaxel, drug-refractory tumors, 
pyrrolopyrimidine  
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1. Introduction 
 
Despite recent innovations in targeted anticancer strategies over the last decade, non-selective 
chemotherapies are still widely used for the clinical management of various patients with 
advanced malignancies [1]. Microtubules represent one of the most common targets for 
chemotherapies, as they are crucial for the maintenance of cell shape, intracellular transport, 
cell motility, and chromosome migration during cell division [2]. Taxanes and vinca-alkaloids 
are the two main classes of microtubule-targeting agents and are classically known to induce 
microtubule stabilization and depolymerization, respectively [3]. Therapeutic doses of all 
compounds from these two families lead to the alteration of the dynamic state of the 
microtubules, which ultimately induces multipolar divisions and causes cell death [4, 5]. 
Beyond their cytotoxic activity, most microtubule-binding agents display antimetastatic, 
antiangiogenic or vascular-disrupting properties, supporting their use as therapeutic agents for 
cancer treatment [6-8]. However, the troublesome side effects of microtubule inhibitors, 
particularly myelosuppression and peripheral neurotoxicity, and the emergence of 
chemoresistance, predominantly from the overexpression of efflux transporters, drastically 
limits their therapeutic outcomes [3], hence underscoring the need for alternative agents. 
We recently identified a novel pyrrolopyrimidine-based microtubule-depolymerizing agent 
(PP-13) that was effective in vitro on a wide range of human cancer cells [9]. PP-13 has no 
kinase activity, directly binds to the colchicine binding site of β-tubulin, interferes with 
microtubule organization and induces spindle multipolarity, transient mitotic cell cycle arrest 
and apoptosis [9]. Interestingly, in marked contrast to conventional microtubule-damaging 
drugs, PP-13 escapes resistance mechanisms linked to the presence of efflux pumps, which 
underlies its potential anticancer activity for multidrug-resistant cancer cells [9].  
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Based on the efficacy of PP-13 against human cancer cell proliferation and multidrug-
resistant cancer cells, the aim of the present study was to investigate the therapeutic potential 
of PP-13 against highly invasive and aggressive cancer cell lines in vitro and in vivo. The 
effects of PP-13 were analyzed in HeLa cervical cancer cells, A549 NSCLC cells and 4T1 
murine mammary cancer cells that were cultured in two-dimensions monolayers or in three-
dimensions-spheroids. The impact of PP-13 on cell migration, metastasis and angiogenesis 
was evaluated. Since no colchicine binding-site agent is currently used in clinic for cancer 
treatment, we assessed the clinical potential of PP-13 activity in comparison with paclitaxel, a 
standard anti-mitotic chemotherapy that is routinely used for the treatment of a wide range of 
solid cancers, and is considered a reference treatment for in vitro and in vivo studies of new 
microtubule-targeting agents. 
 
2. Material and Methods 
 
2.1. Materials 
 
Paclitaxel was obtained from Sigma-Aldrich (Saint-Quentin-Fallavier, France). PP-13 was 
obtained from Institut Curie (CNRS Chemical library, 2004 version), as described in [9]. All 
drugs were dissolved in sterile anhydrous dimethyl sulfoxide (DMSO, Carl Roth, Karlsruhe, 
Germany) at a 10 mmol.L-1 stock solution. Phospho-histone H3 (H3P), and active caspase-3 
antibodies were purchased from Cell Signaling Technology (Ozyme, Saint-Quentin-Les-
Yvelines, France), and conjugated Alexa Fluor 633 goat anti-rabbit antibodies were from 
Thermo Fisher Scientific (Saint-Aubin, France). 
 
2.2. Cell lines and culture 
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The human HeLa and A549 cell lines and the murine 4T1 cells were obtained from the 
American Type Culture Collection (ATCC, Manassas, VA, USA). HeLa cells expressing 
mEGFP-α-tubulin and mRFP-H2B (HeLa-EGFP/RFP) were a generous gift from Dr. D. 
Gerlich [10]. The 4T1 cells were stably transfected with a plasmid expressing the fusion 
histone H2B-RFP (provided by Dr. C. Albigès-Rizo, Institute for Advanced Biosciences, 
Grenoble, France) (4T1-RFP) or with the pGL4.50[luc2/CMV/Hygro] vector encoding the 
firefly luciferase reporter gene luc2 (Promega, Charbonnière, France) (4T1-rvLuc2) using 
JetPEI (Polyplus Transfection, Illkirch, France) according to the manufacturer’s protocol. 
Transfected cells were selected with G418 antibiotic (Invivogen Europe, Toulouse, France, 
ant-gn-5) and amplified. All cells were routinely tested for the presence of mycoplasma 
(MYCOALERT® Mycoplasma Detection Kit, Lonza, Amboise, France) and used within three 
months after thawing. A549, HeLa, and HeLa-EGFP/RFP cell lines were authenticated by 
DNA STR profiling (ATCC Cell line Authentication Service, Manassas, VA, USA). Human 
umbilical vein endothelial cells (HUVECs, passage two to five; Lonza) were cultured in 
complete medium of the EGM-2 BulletKit (Lonza, Amboise, France). 
 
2.2.1. Two-dimensions (2D) cell culture 
Cells were maintained in culture at 37°C in the appropriate medium with 10% FBS in a 5% 
CO2 humidified atmosphere, and the cell morphology was routinely checked.  
 
2.2.2. Three-dimensions (3D) cell culture 
Spheroids were generated by plating A549 (4000 cells/well), HeLa-EGFP/RFP (1000 
cells/well), or 4T1-RFP (2000 cells/well) cells into 96-well round bottom ultra-low 
attachment (ULA) spheroid microplates (Corning, Tewksbury, MA, USA). The spheroid 
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 6 
culture was performed in medium with 10% FBS in a humidified atmosphere with 5% CO2. 
Spheroid formation and growth were assessed by microscopic examination using an inverted 
microscope and by imaging the spheroids at each time point.  
 
2.3. In vitro cytotoxicity assays 
 
Cell proliferation assays were conducted in 96-well culture plates. 2D-cultured cells and 
spheroids were cultured for 24 h and 72 h, respectively, prior to treatment with PP-13 or 
paclitaxel in medium containing 10% FBS for 72 h. The cell viability was quantified using 
CELLTITER 96® AQueous One Solution cell proliferation assay (Promega, Charbonnière, 
France) in 2D cell models or by using the CELLTITER-GLO® 3D Cell Viability Assay 
(Promega, Charbonnière, France) in spheroids. The drug concentrations required to inhibit 
cell growth by 50% (IC50) were interpolated from the dose-response curves.  
 
2.4. Immunofluorescence analyses of spheroids 
 
After PP-13 treatment, the spheroids were washed, fixed overnight at 4°C in 4% 
paraformaldehyde, and then washed, frozen and cut into 7-µm sections before mounting onto 
SuperFrost UltraPlus slides (Thermo Fisher Scientific, Saint-Aubin, France). Cryosections 
were rehydrated in PBS-glycine, permeabilized for 1 h in PBS with 2% Triton X-100, washed 
in PBS-glycine, blocked in 10% goat serum and incubated overnight at 4°C with primary 
antibodies. The sections were then washed in 0.2% Tween-20/PBS and incubated for 1 h with 
conjugated secondary antibodies. Hoechst was used to counterstain the cell nuclei. 
Fluorescence microscopy was carried out using a confocal microscope (LSM 710; Carl Zeiss, 
Jena, Germany). An objective Plan Apochromat 20×/0.8 NA in air and an objective Plan 
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Apochromat 63×/1.4 NA in oil were used. The H3P and active caspase-3 expression levels in 
spheroids were counted based on color thresholding image adjustment using ImageJ software 
(NIH, Bethesda, MD, USA) and the images were blinded. The percentage of H3P was 
calculated as the number of H3P-positive cells in control and PP-13-treated spheroids (n ≥ 7 
as indicated in the figure legends, with three different sections analyzed per spheroid). The 
percentage of cleaved caspase-3 was calculated as the number of cleaved caspase-3-positive 
cells in control and treated spheroids (n ≥ 7 as indicated in the figure legends, with two or 
three different sections analyzed per spheroid). 
 
2.5. Immunoblotting 
 
Western blot analyses were performed as previously described [11] after protein extraction of 
ten pooled spheroids per condition and sonication. H3P and actin intensities were quantified 
using the Image J software and the relative densitometric area for H3P were determined 
according to actin signal in each condition. 
 
2.6. Wound-healing assay 
 
A549, 4T1-rvLuc2 and HeLa cells were seeded into 96-well plates (15000 cells/well) and 
allowed to grow for 24 h until confluence. Scratching the surface with a wound maker 
physically wounded the cell monolayers, and increasing concentrations of PP-13 or DMSO 
were added into the medium. Images of the cells invading the scratch wound were monitored 
for 12 h using the IncuCyte S3 Live-Cell analysis system (Essen Bioscience, Hertfordshire, 
UK). The relative wound density was analyzed using the IncuCyte S3 software.  
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2.7. Transwell migration and invasion assays 
 
A549, 4T1-rvLuc2 and HeLa cells were plated (75000 cells) on top of a transwell chamber 
with Matrigel (Corning, Tewksbury, MA, USA) under starvation conditions, and complete 
medium was added into the well. After 24 h of incubation with PP-13 or DMSO, cells that 
reached the bottom of the transwell were stained with methylene blue and observed by 
microscopy (AxioImager M2, Carl Zeiss, Jena, Germany). Ten images were obtained per 
condition and were blinded for quantification. Cell invasion was quantified using a fully 
connected, three-layer back-propagation neuronal network, as previously described [12]. 
Briefly, the input layer of the network was prepared to receive 12 9 12 pixel images, with 
three-color channels totaling up to 12 9 12 9 3 input neurons. A total of twenty-four neurons 
in the hidden layer were utilized. The output layer consists of two neurons corresponding to 
the two classes E (empty space between structures) and S (structure) with respect to which 
each pixel and its neighborhood were classified. A training set of ~10-20 images of each kind 
were created for training. An extended training set of ~ five hundred pictures per species was 
generated by rotating each picture by twenty-four equidistant angles, as well as rescaling to 
90, 100, and 110% of the original size. Training was performed by (on average) two thousand 
forward passes per extended training set picture, with full error back propagations. Feed-
forward and error-backward propagations employ well-known sigmoidal characteristics based 
on the logistic function. The target signals for the two output neurons were [1, 0] 
corresponding to E, and [0, 1] corresponding to S, respectively.  
 
2.8. In vitro capillary-like tube formation assay 
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A 15-well Ibidi angiogenesis microslide (Ibidi, Clinisciences, Nanterren France) was coated 
with 10 µL of Matrigel matrix (Corning) and incubated for 30 minutes at 37°C for gel 
polymerization. Twenty thousand HUVECs were seeded on top of the polymerized gel matrix 
in complete medium with increasing concentrations of PP-13 or 0.1% DMSO. The microslide 
was then placed in a 37°C heated stage in a 5% CO2 humidified atmosphere. Images were 
acquired after 6 h of incubation by a phase-contrast microscope with an Achromat 5×/0.12 
NA objective, blinded and analyzed using the automated WimTube image analysis tool 
(Wimasis GmbH, Munich, Germany). 
 
2.9. In vivo studies using chick embryo tumor model 
 
A chick embryo tumor growth and metastasis assay (InOvotion, Grenoble, France) was 
performed as previously described [9]. According to French legislation, no ethical approval is 
needed for scientific experimentations using oviparous embryos (decree number 2013–118, 
February 1, 2013; art. R-214–88). Briefly, fertilized white leghorn eggs (SFPA, Hendrix 
Genetics group, Saint Brieuc, France) were incubated at 38°C with 60% relative humidity for 
nine days. The chorioallantoic membrane (CAM) was then dropped, and a 1-cm2 window was 
cut into the eggshell above the CAM (at day nine). A total of three million A549 cells were 
added directly onto the CAM of each egg. The eggs were randomly allocated into three 
groups. Group size was determined based on the expertise of InOvotion showing that n ≥ 15 
was the minimum number of eggs to show significant effects. At day ten, when tumors began 
to be detectable, the eggs were treated every other day for ten days by adding 100 μL of either 
50 μmol.L−1 paclitaxel (n = 17), 0.13 μmol.L−1 PP-13 (n = 18), or 0.5% DMSO in PBS 
(vehicle, n = 18) dropwise onto the tumor. The concentration of paclitaxel was chosen as a 
positive control to induce significant tumor growth inhibition without toxicity for embryos. 
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The concentration of PP-13 has been arbitrarily chosen according to in vitro experiments 
(IC50) and following the expertise of InOvotion. The upper portion of the CAM was then 
removed, and the tumors were carefully cut away and weighed. In parallel, a 1-cm2 portion of 
the lower CAM was collected, genomic DNA was extracted, and qPCR analysis was 
performed by using primers specific for genomic human Alu/repetitive sequences [9] to 
evaluate the number of A549 cells. Finally, scoring the number of dead embryos and looking 
for morphological or functional abnormalities in the surviving embryos was carried out to 
evaluate the toxicity of the treatment. 
 
2.10. In vivo studies using mice tumor model 
 
All animal studies were performed in accordance with the European Economic Community 
guidelines and the “Principles of Laboratory Animal Care” (NIH publication N 86-23 revised 
1985) and were approved by the institutional guidelines and the European Community (EU 
Directive 2010/63/EU) for the use of experimental animals (authorization for the experiment: 
APAFIS#8854-2017031314338357 v1). 
 
Six-week-old female NMRI nude mice (Janvier Labs, Le Genest-Saint Isle, France) were 
anesthetized using 4% isoflurane/air for anesthesia induction and 1.5% thereafter, and 
luciferase-modified mouse 4T1 cancer cells (4T1-rvLuc2 cells, 20000 cells per 50 µL) were 
injected into the mammary fat pad. The mice were immediately randomly divided into four 
groups of eight mice, receiving vehicle (0.9% NaCl, 1% DMSO, 30% PEG, 1% Tween-80, 
referred to as control), 0.5 mg.kg-1 paclitaxel, 0.5 mg.kg-1 PP-13, or 1 mg.kg-1 PP-13. Group 
size was determined based on our expertise showing that n ≥ 8 per group was the minimum 
number of mice to show significant effects on metastases. Based on the results obtained on 
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chick embryo tumor model showing the effect of PP-13 at very low dose, two low 
concentrations of PP-13 were chosen (0.5 and 1 mg.kg-1). Similar low concentration (0.5 
mg.kg-1) was chosen for paclitaxel to compared this standard chemotherapy with PP-13, and 
based on preliminary experiments showing sub-therapeutic effect of 0.5 mg/kg-1 paclitaxel on 
tumor and metastases growth (data not shown). Intraperitoneal administration of 200 µL of 
treatment was performed three times per week for five weeks. The mice were examined daily 
for behavior and morbi-mortality and were weighed three times per week. The primary tumor 
growth was monitored three times per week using a caliper, and the tumor volume was 
calculated as follows [13]: tumor volume = length x width  x 0.4. The thoracic metastasis 
growth was followed once per week by in vivo bioluminescence imaging (IVIS KINETIC, 
Perkin Elmer, Waltham, MA, USA) 5 min after the intraperitoneal injection of 150 mg.kg-1 of 
luciferin (Promega, E1605), as previously described [14]. Twenty-two days after 4T1-rvLuc2 
cell implantation, 0.1 mg.kg-1 buprenorphine was injected subcutaneously for analgesia and 
the primary breast tumors were excised under general anesthesia. The mice were carefully 
observed during the day following the surgery. After five weeks, the mice were sacrificed and 
blood samples were collected by cardiac puncture using a heparinized syringe. The lungs, 
axillary and brachial lymph nodes, kidney and liver were harvested for further imaging and/or 
analyses.  
 
2.11. Ex vivo studies of mice tissue samples 
 
Blood samples were evaluated for hematological parameters with a medical automated 
hematology analyzer (Micros-60, Horiba ABX, Montpellier, France), and biochemical 
analyses were performed by the Charles Rivers Laboratory (Massachusetts, USA). Bone 
marrow was obtained after having carefully sectioned mice femurs at each joint and flushing 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 12 
the bone cavity with PBS. Cells from the plasma and bone marrow samples were washed in 
PBS, cytospun (Cytospin 4, Fisher Scientific, Illkirch, France) and stained with May-
Grunwald-Giemsa solution (MGG) with the automated XE-5000 Instrument (Sysmex, Roissy, 
France). Global cell abundance evaluation and megakaryocyte and leukocyte counting were 
then performed for both samples by an experienced hematologist. 
Tumor tissues were frozen in OCT-embedding medium (VWR international, Fontenay-sous-
Bois, France) and cut into 7 μm thick sections using a cryomicrotome for 
immunohistochemical analyses. Immunohistochemical examinations were performed after 
fixation with 4% paraformaldehyde and staining with anti-CD31 antibody (Pharmingen, BD 
Biosciences, Le Pont de Claix, France), using an AxioImager M2 microscope (Carl Zeiss, 
Jena, Germany). Segmentation of tissues was performed using a fully connected, three-layer 
back-propagation neuronal network, as previously described [12]. 
 
2.12. Statistical analyses 
 
All analyses were performed using the GraphPad Prism software (GraphPad Software Inc., 
San Diego, California, USA). Statistical comparisons between two groups or more were 
conducted with Mann-Whitney test, Kruskal-Wallis test, or Friedman test with Dunn’s 
multiple comparisons post hoc test. Statistical comparisons between mice groups among time 
were determined by two-way ANOVA with Bonferroni’s post hoc test. Statistical significance 
was defined for p values ≤0.05.  
 
3. Results 
 
3.1. PP-13 treatment decreases cancer cell proliferation in vitro 
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To investigate the therapeutic effect of PP-13, we chose three cell lines displaying high levels 
of proliferation, migration and invasiveness: the human HeLa cervical cell line and its 
derivative subclone expressing mEGFP-D-tubulin and mRFP-H2B (HeLa-EGFP/RFP), the 
human A549 lung cancer cell line, and the mouse 4T1 mammary cancer cells expressing 
mRFP-H2B (4T1-RFP) or luciferase (4T1-rvLuc2). We first analyzed the toxicity of PP-13 in 
these cell lines cultured in monolayers or in 3D-spheroids. PP-13 had a significant effect on 
the proliferation of these cell lines, strongly reducing their viability (Fig. 1A). The IC50 values 
of PP-13 (50% growth inhibition) were relatively similar for the three cell lines cultured in 
monolayers (Table 1) [9]. These IC50 values did not vary significantly when the cells were 
grown in spheroids, except for A549 (Table 1 and Fig. 1A and 1B). Indeed, the A549 
spheroids appeared to strongly resist PP-13 treatment compared to A549 cells in the 
monolayer cell culture. Similar effects were observed in these cell lines with the reference 
antimitotic chemotherapy paclitaxel (Table 1 and Fig. 1). We have shown that paclitaxel has a 
reducing effect on 4T1 cell viability in 2D culture compared to A549 (~five-fold lower) and 
HeLa (~ten-fold lower) cells, thus reflecting the resistance of 4T1 cells to paclitaxel. In 
addition, although 4T1-RFP spheroids were surprisingly more sensitive to low doses of 
paclitaxel than monolayer 4T1-RFP cells, high concentrations of paclitaxel failed to inhibit 
more than 50% of the cell proliferation of both A549 and 4T1 spheroids. Thus, PP-13 affected 
the proliferation of invasive cells in vitro, including those that are resistant to paclitaxel. 
 
3.2. PP-13 treatment induces mitotic blockade in cancer cell spheroids 
 
We previously demonstrated that PP-13 induced a transient mitotic blockade by interfering 
with mitotic spindle organization and microtubule dynamics in monolayer cell cultures [9]. 
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Here, we analyzed the effect of PP-13 on mitosis in spheroids. The cell viability of HeLa-
EGFP/RFP spheroids was not impacted by a short 24 h treatment of 200 nmol.L-1 PP-13 (data 
not shown). Alpha-tubulin and phosphorylated histone H3 (H3P), a marker of late G2/M cell 
cycle phase, were analyzed by confocal microscopy on HeLa-EGFP/RFP spheroid sections 
(Fig. 2A). We observed that PP-13 led to mitotic defects, including multiple misoriented and 
shortened mitotic spindles (green arrows) associated with chromosomes miscongression (blue 
arrows). In addition, we showed a significant increase in the level of H3P after 24 h of PP-13 
treatment, reflecting the strong accumulation of cells in mitosis in the HeLa-EGFP/RFP 
spheroids (Fig. 2C). As expected, paclitaxel also enhanced the level of H3P in HeLa-
EGFP/RFP spheroids but to a lower extent than PP-13 and with an effect mainly on the cells 
at the periphery of the spheroids (Fig. 2B and 2C). Accumulation of H3P in response to PP-13 
treatment was also increased in A549 spheroids compared to untreated control (Fig. 2C), and 
was confirmed by western blot of the three spheroid types (Fig. 2D). Finally, after 72 h of PP-
13 treatment, the HeLa-EGFP/RFP spheroids showed a significant increase in cleaved 
caspase-3 (Fig. 2E and 2F). Therefore, in spheroid cultures, PP-13 induced mitotic spindle 
disorganization, mitotic blockade, inhibition of cell growth and apoptosis. 
 
3.3. PP-13 inhibits angiogenesis in vitro 
 
Because most of the microtubule-targeting agents also exhibit antiangiogenic properties [3, 6, 
15, 16], we investigated the effects of PP-13 on capillary-like structure formation in vitro 
using HUVECs plated on a Matrigel basement membrane. In control conditions, endothelial 
cells aligned and formed organized networks of capillary-like structures after 6 h (Fig. 3A). 
PP-13 treatment reduced the total number of branching points, the number of loops, the length 
of the tubes, and the total cell-covered area compared to the control (Fig. 3B). Altogether, PP-
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13 altered the ability of HUVECs to form tube-like structures. The concentrations of PP-13 
that were used had limited impact on HUVEC proliferation (Fig. 3C). Hence, this suggested 
that PP-13 displayed antiangiogenic properties in vitro. 
 
3.4. PP-13 inhibits the migration of cancer cells in vitro 
 
Given the essential role of microtubules in cell motility, we investigated whether the PP-13 
tubulin inhibitor impacted HeLa, A549, and 4T1-rvLuc2 cell migration and invasiveness in 
vitro. The impact of PP-13 on the motility of cells was examined using an in vitro wound-
healing assay. We observed that PP-13 significantly reduced the motility of the three cell lines 
in a dose-dependent manner, and as paclitaxel (Fig. 4A and 4B). The effect of PP-13 on 
invasive migration was assessed with Matrigel in transwell chambers. PP-13 exerted a strong 
inhibitory effect on the invasion of the three cell lines (Fig. 4C and 4D). Paclitaxel also 
inhibited the invasion of these cells. These results indicated that PP-13 is able to slow down 
cell motility and invasion in vitro. 
 
3.5. PP-13 inhibits the migration of cancer cells in vivo 
 
We previously showed that PP-13 reduces tumor growth and metastatic invasion in vivo by 
using H358 NSCLC cells engrafted onto chicken chorioallantoic membranes (CAMs) [9]. 
Here, we used A549 NSCLC cells engrafted onto the CAMs to evaluate the efficacy of PP-13 
on the migration of invasive cancer cells. The tumors were treated every other day with 
vehicle (control), PP-13, or paclitaxel (Fig. 5A). At the end of the experiment, the tumors 
were recovered from the upper CAMs and weighed. We used a very low concentration of PP-
13 (0.13 μmol.L-1) compared to the > 10 µmol.L-1 PP-13 IC50 in the A549 spheroid cell 
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culture (Table 1), which did not inhibit A549 tumor growth (Fig. 5B). Analysis of the 
presence of A549 cells at the lower CAM by qPCR, allowing for the accurate detection of 
tumor cell dissemination, showed that this low dose of PP-13 significantly reduced the 
metastatic ability of A549 cells compared to the control (Fig. 5C). Paclitaxel was used as a 
positive control at a concentration known to inhibit A549 tumor growth and metastatic 
dissemination without inducing significant toxicity (Fig. 5B and 5C) [9]. These results 
suggested that PP-13 inhibited invasion in vivo. Furthermore, treatment with PP-13 did not 
significantly increase the mortality (two embryos died in the control group, and one embryo 
died in both paclitaxel and PP-13-treated groups) or abnormalities (no abnormality observed 
on surviving embryos for the different experimental groups) on chicken embryos, indicating 
that it was well tolerated. 
 
3.6. PP-13 impairs tumor progression and metastasis in an allogeneic breast cancer 
model 
 
To further evaluate the effect of PP-13 on tumor growth and metastasis formation, we used 
the allogeneic model of 4T1-rvLuc2 cell engraftment in the mammary fat pads of mice. We 
chose this model because once engrafted orthotopically in the mammary gland, 4T1-rvLuc2 
mouse cancer cells metastasize to multiple distant sites (lymph nodes, lungs, liver, bone, 
brain), thus mimicking human breast cancers [17]. As soon as the 4T1-rvLuc2 cells were 
inoculated, the mice were randomly divided into four groups: one control group, one group 
treated with paclitaxel (0.5 mg.kg-1) and two groups treated with PP-13 (0.5 and 1 mg.kg-1) 
(Fig. 5D). The low concentrations of PP-13 were chosen based on the results obtained on 
chick embryo tumor model showing an inhibitory effect of PP-13 at very low dose, and were 
compared to the same concentration of the standard chemotherapy paclitaxel. Intraperitoneal 
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injections of each treatment were performed three times per week. The tumor progression was 
not affected at early time points, but the final tumor volumes were significantly lower after 
three weeks for the two groups treated with PP-13 in this rapidly progressing breast cancer 
model (Fig. 5E). The potential antiangiogenic activity of PP-13 in vivo was assessed sections 
performed on primary tumors stained with an anti-CD31 antibody. The microvessel density 
was counted and showed no significant difference between the treatments at the 
concentrations used and at this time-point (Fig. 5F). No significant difference between the 
treatments was observed in Ki67 immunostaining either (data not shown). 
 
In vivo bioluminescence imaging was used to follow the development of thoracic metastases 
before and after primary tumor resection. Paclitaxel had no effect on the bioluminescence 
signal compared to the control treatment and even slightly enhanced it at day 28 (Fig. 6A and 
6B). In contrast, the signal of thoracic metastasis was reduced with PP-13 treatment. Of note, 
both PP-13 and paclitaxel treatment reduced the number of mice with thoracic metastases 
compared to the control treatment from 2 weeks of treatment (Table 2). These results were 
confirmed by measuring bioluminescence in the lungs ex vivo at the end of the experiment 
(day 35) (Fig. 6C). This showed a non-significant 66% reduction in the lung metastasis signal 
in mice treated with 1 mg.kg-1 PP-13 compared to control mice (Fig. 6D). In addition, ex 
vivo, the axillary and brachial lymph nodes showed a significant decrease in signal in both of 
the PP-13-treated groups compared to the control and paclitaxel-treated groups (Fig. 7A and 
7B). The percentage of mice with axillary and brachial lymph node metastases was reduced in 
a dose-dependent manner in the PP-13-treated groups compared to the control and paclitaxel-
treated groups (Table 2), as was the number of metastatic axillary and brachial lymph nodes 
(Fig. 7A). Taken together, these results showed that PP-13 decreased tumor and metastatic 
dissemination in this breast cancer model. 
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3.7. PP-13 shows no adverse side effects in vivo 
 
We assessed the toxicity of PP-13 and paclitaxel in vivo. There was no body-weight loss in 
the control and PP-13-treated mice over the course of the experiment, while mice exposed to 
paclitaxel displayed a significant decrease in body weight at the end of the experiment (Table 
3). In addition, one of the eight mice in each of the paclitaxel and control groups died before 
the end of the experiment probably because of tumor progression, while all PP-13-treated 
mice survived suggesting that PP-13 may control tumor progression. 
 
We paid particular attention to some of the side effects described for conventional spindle 
poisons in patients. Serum biochemical analysis showed significant decreases in phosphorus, 
creatinine, and glucose in paclitaxel-treated mice compared to the control group (Table 4). No 
significant changes in serum biochemical values were reported in PP-13-treated mice, except 
a small and isolated decrease in blood urea nitrogen that did not reflect any renal toxicity in 
this context. In addition, macroscopic analyses of the organs of the treated mice did not show 
evidence of damage (data not shown). Hematological analysis of the blood and bone marrow 
cells from mice treated with PP-13 did not reveal any apparent signs of myelosuppression or 
other hematological abnormalities compared to the control (Table 5). In contrast, paclitaxel 
treatment led to a significant reduction in the white blood cell (WBC) count and a slight 
increase in the mean corpuscular hemoglobin concentration (MCHC). 
Overall, these data suggest that PP-13 displays a favorable safety profile, as it slows both 
tumor and metastasis progression and is well tolerated at these doses compared to the control 
and paclitaxel. 
 
4. Discussion 
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The new pyrrolo[2,3d]pyrimidine-based colchicine-binding site agent PP-13 showed 
promising anticancer properties in vitro [9]. In this study, we explored the therapeutic 
potential of PP-13, particularly in conditions leading to invasive cancer cell phenotype, and 
compared the effects of PP-13 with those of paclitaxel, a widely used tubulin-targeting agent 
in solid tumors. We showed that PP-13 inhibited proliferation, migration and angiogenesis in 
vitro, which may potentiate its antineoplastic activity, and reduced metastatic dissemination in 
paclitaxel-resistant tumors in vivo, with no detectable adverse side effects. 
 
We confirmed the in vitro antitumor effects of PP-13 in spheroids. The PP-13-treated 
spheroids showed enhanced H3P levels associated with defects in mitotic spindle organization 
and chromosome congression, thus confirming in three-dimensions models that PP-13 
induced an early mitotic blockade. Late caspase-3-dependent apoptotic mechanisms 
contributed to the decrease in spheroid growth, as was previously described in two-
dimensions cell cultures [9]. Spheroids are currently considered to be a more suitable model 
than monolayer cell cultures because they better mimic the in vivo three-dimensions tumor 
environment and cell-cell and cell-extracellular matrix interactions [18-20]. Large spheroids 
(≥ 300 µm diameter), such as those generated in our experiments, display a hypoxic core 
resulting from chemical gradients of oxygen and nutrients that are correlated with 
chemoresistance, as reported in developing tumors [21]. We observed differences in the IC50 
values of PP-13 between monolayer cell culture and spheroids. In particular, A549 cells were 
resistant to PP-13 when cultured in spheroids, in contrast to monolayer cell culture, 
suggesting that the effect of PP-13 observed on two-dimensions-culture cell proliferation is 
reduced in spheroids. The presence of various environmental factors affecting the tumor 
development (e.g., cell–cell adhesion, cell-cycle distribution, local pH, extracellular matrix) 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 20 
[20] could explain the lower sensitivity of spheroid cancer cells to drugs compared to two-
dimensions cell cultures, as was also observed in different in vivo tumor models [22-24]. The 
physicochemical properties of PP-13 could also be responsible for the lower sensitivity in 
three-dimensions cell culture. 
Despite opposite mechanisms of action (microtubule stabilization or depolymerization) [3], 
both PP-13 and paclitaxel lead to the disruption of the microtubule organization and the 
induction of cancer cell cycle arrest and apoptosis. 
Angiogenesis and cancer cell migration are attractive therapeutic targets [25]. The widely 
used capillary-like tube formation assay aids in studying the effects of new molecules on 
many steps of neoangiogenesis, including endothelial cell adhesion, migration, and tubule 
formation [26]. With this approach, we showed that PP-13 interfered with the tubule assembly 
in vitro by decreasing both the number of loops and branch nodes, the total length of the formed 
tubes and the cell-covered area. Using in vivo 4T1 primary breast tumor models, we did not 
observe any impact of PP-13 on microvessel density, suggesting that such PP-13 
concentrations were inadequate to induce antiangiogenic activities and/or that the study time 
was not suitable to inhibit endothelial cells in vivo in this rapidly progressing breast cancer 
orthotopic model.  
 
PP-13 inhibited cell motility and invasion both in vitro and in vivo. In vitro, we found that 
PP-13 inhibited cancer cell migration in the three metastatic tumor cell types. In addition, PP-
13 reduced metastatic invasion in H358 [9] and A549 NSCLC cells engrafted onto chicken 
CAMs at concentrations that did not inhibit cell proliferation in A549 spheroids. Accordingly, 
PP-13 did not inhibit A549 tumor growth in chicken CAMs. This confirmed the lower effect 
of PP-13 on cell proliferation in spheroids and in vivo compared to monolayer cell culture. 
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The orthotopic mouse model of breast cancer that was used is clinically relevant to predict the 
influence of the organ microenvironment on tumor cell behavior and to study the cancer cell 
invasion and metastatic growth [27]. Although PP-13 did not inhibit in vivo tumor cell 
migration and metastasis seeding at the concentrations used, we observed that the growth of 
the metastases was delayed, and their size remained small in both lungs and lymph nodes 
when the cells migrated from the primary tumor. Although PP-13 had both antiproliferative 
and antimigration effects in vitro, the in vivo experiments indicated that the effect of the drug 
on the inhibition of invasion was stronger than its antiproliferative effects. 
 
Overall, our data indicate that PP-13 could be a potent agent to decrease the growth of both 
primary tumors and their metastases, especially for triple-negative breast cancers (TNBC), 
which account for nearly 15% of breast cancers and have poor therapeutic options and 
prognoses [28]. The 4T1 allogeneic transplant mouse model mimics TNBC in humans and is 
associated with a high propensity to metastasize, primarily in the lymph nodes and lungs. The 
therapeutic arsenal for TNBC mainly consists of anthracyclines and taxane-based 
chemotherapies; however, the emergence of resistance and frequent tumor recurrence support 
the need to identify alternative drugs for the management of refractory tumors. The 4T1 
model thus represents an interesting approach to screen new molecules for TNBC therapy, 
especially since it spontaneously metastasizes in the same regions as in TNBC and easily 
develops resistance to chemotherapies classically used in TNBC [29, 30]. Compared to 
paclitaxel, which was used as a reference treatment to reduce metastasis while limiting the 
adverse effects, PP-13 moderately inhibited primary tumor growth and delayed metastatic 
growth.  
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PP-13 treatment did not show any sign of toxicity compared to the controls; there was notably 
an absence of myelosuppression, which is classically observed with conventional antimitotic 
drug treatments or colchicine binding-site agents [3]. At the same dose, paclitaxel led to a 
significant decrease in white blood cell count, as has been previously reported [31], as well as 
a slight reduction in plasma glycaemia, phosphorus and creatinine and an increase in MCHC. 
Further investigations with higher concentrations of PP-13 will be needed to establish the 
maximal antitumor effect of PP-13, and the therapeutic index of the molecule, and long-term 
survival. In addition, PP-13 has no kinase activity [9] but may target other molecule than 
tubulin, that remains to determine. 
 
In summary, PP-13 significantly reduced the cancer cell migration and neoangiogenesis 
processes in vitro. PP-13 also led to a reduction in both tumor growth and metastatic 
dissemination in vivo in a mouse orthotopic TNBC model without any significant toxicity. 
These findings suggest that PP-13 should be an efficient anticancer therapy and an alternative 
option to conventional spindle poisons such as taxanes or vinca-alkaloids. 
 
5. Acknowledgements 
 
We acknowledge the assistance of Alexeï Grichine, Mylène Pezet and Jacques Mazzega 
(Optical Microscopy Platform - Cell Imaging, INSERM U1209). We kindly thank Dr. Lucie 
Sancey for critical evaluation of the data, and Lilya Mediouni for her help. This work was 
supported by the Institut Curie, the CNRS, the INSERM, and grants from “La Fondation de 
France” and “La Ligue contre le Cancer (comité de l’Isère)”. The in vivo evaluation was 
performed by the OPTIMAL facility, which is part of the France Live Imaging Program (FLI-
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 23 
Grenoble; French program “Investissement d’Avenir”; grant “Infrastructure d’avenir en 
Biologie Santé,” ANR-11-INBS-0006). 
 
6. Author contributions 
 
PG, BB, and AH conceived the project, designed the experiments, and interpreted the data. 
PG, LL, MC, LV, MH, and JV were involved in acquisition, analysis and interpretation of the 
data. VB, MW, and AO managed automated quantifications. VJ, MH, and JV designed the in 
vivo experiment. FMB synthesized and characterized PP-13. JLC, BB and AH supervised the 
research and analyses. PG, BB and AH supervised the whole project and wrote the 
manuscript. All authors reviewed the manuscript. 
 
7. References 
 
[1] K.D. Miller, R.L. Siegel, C.C. Lin, A.B. Mariotto, J.L. Kramer, J.H. Rowland, et al., 
Cancer treatment and survivorship statistics, 2016, CA Cancer J Clin 66(4) 2016: 271-89. 
[2] M.A. Jordan, L. Wilson, Microtubules as a target for anticancer drugs, Nat Rev Cancer 
4(4) 2004: 253-65. 
[3] C. Dumontet, M.A. Jordan, Microtubule-binding agents: a dynamic field of cancer 
therapeutics, Nat Rev Drug Discov 9(10) 2010: 790-803. 
[4] M.A. Jordan, Mechanism of action of antitumor drugs that interact with microtubules and 
tubulin, Curr Med Chem Anticancer Agents 2(1) 2002: 1-17. 
[5] D. Fanale, G. Bronte, F. Passiglia, V. Calo, M. Castiglia, F. Di Piazza, et al., Stabilizing 
versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment 
option?, Anal Cell Pathol (Amst) 2015 2015: 690916. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 24 
[6] E.L. Schwartz, Antivascular actions of microtubule-binding drugs, Clin Cancer Res 15(8) 
2009: 2594-601. 
[7] C. Kanthou, G.M. Tozer, Microtubule depolymerizing vascular disrupting agents: novel 
therapeutic agents for oncology and other pathologies, Int J Exp Pathol 90(3) 2009: 284-94. 
[8] D. Bates, A. Eastman, Microtubule destabilising agents: far more than just antimitotic 
anticancer drugs, Br J Clin Pharmacol 83(2) 2017: 255-268. 
[9] P. Gilson, J.F. Josa-Prado, C. Beauvineau, D. Naud-Martin, L. Vanwontherghem, F. 
Mahuteau-Betzer, et al., Identification of pyrrolopyrimidin derivative PP-13 as a novel 
microtubule-destabilizing agent with promising anticancer properties, Scientific Reports 7 
2017: 10209. 
[10] P. Steigemann, C. Wurzenberger, M.H. Schmitz, M. Held, J. Guizetti, S. Maar, et al., 
Aurora B-mediated abscission checkpoint protects against tetraploidization, Cell 136(3) 2009: 
473-84. 
[11] B. Busser, L. Sancey, V. Josserand, C. Niang, M.C. Favrot, J.L. Coll, et al., 
Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung 
cancers, Molecular therapy 18(3) 2010: 528-35. 
[12] Q. Zheng, B.K. Milthorpe, A.S. Jones, Direct neural network application for automated 
cell recognition, Cytometry A 57(1) 2004: 1-9. 
[13] B. Busser, L. Sancey, V. Josserand, C. Niang, S. Khochbin, M.C. Favrot, et al., 
Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating 
Ku70 acetylation, Molecular therapy 18(3) 2010: 536-43. 
[14] V. Jeannot, S. Mazzaferro, J. Lavaud, L. Vanwonterghem, M. Henry, M. Arboleas, et al., 
Targeting CD44 receptor-positive lung tumors using polysaccharide-based nanocarriers: 
Influence of nanoparticle size and administration route, Nanomedicine 12(4) 2016: 921-32. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 25 
[15] E. Pasquier, S. Honore, D. Braguer, Microtubule-targeting agents in angiogenesis: where 
do we stand?, Drug Resist Updat 9(1-2) 2006: 74-86. 
[16] E. Pasquier, N. Andre, D. Braguer, Targeting microtubules to inhibit angiogenesis and 
disrupt tumour vasculature: implications for cancer treatment, Curr Cancer Drug Targets 7(6) 
2007: 566-81. 
[17] B.A. Pulaski, S. Ostrand-Rosenberg, Mouse 4T1 breast tumor model, Curr Protoc 
Immunol Chapter 20 2001: Unit 20 2. 
[18] C.J. Lovitt, T.B. Shelper, V.M. Avery, Advanced cell culture techniques for cancer drug 
discovery, Biology (Basel) 3(2) 2014: 345-67. 
[19] F. Hirschhaeuser, H. Menne, C. Dittfeld, J. West, W. Mueller-Klieser, L.A. Kunz-
Schughart, Multicellular tumor spheroids: an underestimated tool is catching up again, 
Journal of biotechnology 148(1) 2010: 3-15. 
[20] G. Mehta, A.Y. Hsiao, M. Ingram, G.D. Luker, S. Takayama, Opportunities and 
challenges for use of tumor spheroids as models to test drug delivery and efficacy, Journal of 
controlled release : official journal of the Controlled Release Society 164(2) 2012: 192-204. 
[21] S. Daster, N. Amatruda, D. Calabrese, R. Ivanek, E. Turrini, R.A. Droeser, et al., 
Induction of hypoxia and necrosis in multicellular tumor spheroids is associated with 
resistance to chemotherapy treatment, Oncotarget 8(1) 2017: 1725-1736. 
[22] R. Edmondson, J.J. Broglie, A.F. Adcock, L. Yang, Three-dimensional cell culture 
systems and their applications in drug discovery and cell-based biosensors, Assay Drug Dev 
Technol 12(4) 2014: 207-18. 
[23] S. Breslin, L. O'Driscoll, The relevance of using 3D cell cultures, in addition to 2D 
monolayer cultures, when evaluating breast cancer drug sensitivity and resistance, Oncotarget 
7(29) 2016: 45745-45756. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 26 
[24] V.S. Nirmalanandhan, A. Duren, P. Hendricks, G. Vielhauer, G.S. Sittampalam, Activity 
of anticancer agents in a three-dimensional cell culture model, Assay Drug Dev Technol 8(5) 
2010: 581-90. 
[25] D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation, Cell 144(5) 2011: 
646-74. 
[26] D. Xie, D. Ju, C. Speyer, D. Gorski, M.A. Kosir, Strategic Endothelial Cell Tube 
Formation Assay: Comparing Extracellular Matrix and Growth Factor Reduced Extracellular 
Matrix, J Vis Exp (114) 2016. 
[27] S. Man, R. Munoz, R.S. Kerbel, On the development of models in mice of advanced 
visceral metastatic disease for anti-cancer drug testing, Cancer Metastasis Rev 26(3-4) 2007: 
737-47. 
[28] P. Kaur, G.M. Nagaraja, H. Zheng, D. Gizachew, M. Galukande, S. Krishnan, et al., A 
mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits 
similar aggressive phenotype to the human disease, BMC Cancer 12 2012: 120. 
[29] L. Bao, A. Haque, K. Jackson, S. Hazari, K. Moroz, R. Jetly, et al., Increased expression 
of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast 
cancer model, Am J Pathol 178(2) 2011: 838-52. 
[30] T. Luo, J. Wang, Y. Yin, H. Hua, J. Jing, X. Sun, et al., (-)-Epigallocatechin gallate 
sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma, Breast 
Cancer Res 12(1) 2010: R8. 
[31] E.A. Perez, Paclitaxel in Breast Cancer, Oncologist 3(6) 1998: 373-389. 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 27 
Figure legends 
 
Table 1: Sensitivity of cancer cell lines to PP-13 and paclitaxel. The drug concentrations 
required to inhibit cell growth by 50% (IC50) at 72h in HeLa cells, HeLa mEGFP-α-tubulin and 
mRFP-H2B cells (HeLa-EGFP/RFP), A549 cells, 4T1 mRFP-H2B cells (4T1-RFP) and 4T1-rvLuc2 
cells cultured in 2D-monolayer (2D) or spheroids. Data represent the mean ± SD of three independent 
experiments, each performed in triplicate. 
 
Table 2: PP-13 decreased the number of mice with thoracic and lymph node metastases. 
Mice with 4T1-rvLuc2 tumors were treated with vehicle (control), paclitaxel 0.5 mg.kg-1, or 
PP-13 (0.5 and 1 mg.kg-1) (see Fig. 5D). Number and percentages of mice with thoracic 
metastases at day 14, and with invaded axillary and brachial lymph nodes at day 35 are shown 
in each group. 
 
Table 3: Mice body-weight. Mice with 4T1-rvLuc2 tumors were treated with vehicle 
(control), paclitaxel 0.5 mg.kg-1, or PP-13 (0.5 and 1 mg.kg-1) (see Fig. 5D). Mice body-
weight is expressed as mean ± SEM (n=8, except in paclitaxel-treated group at day 35, n=7), 
and as percentage of initial body-weight (day 0). * p <0.05; two-way ANOVA with 
Bonferroni post-test (day 35 compared to day 28). 
 
Table 4: Biochemical analyses of mice. Plasma biochemical values of mice after control, 
paclitaxel or PP-13 treatments were assessed. Data represent the mean ± SD of 6 mice per 
group. Data were analyzed using Mann-Whitney U-test. * Significant as compared to control 
group. 
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Table 5: Hematological and bone marrows analyses of mice. Complete blood count and 
white blood cells count and evaluation of the global cell abundance and megakaryocyte and 
leukocyte counts in the bone marrow, from mice treated with control, paclitaxel, or PP-13. 
Data represent the mean ± SD of 8 mice per group. # from score 1 (low abundance) to score 4 
(high abundance). Data were analyzed using one-way analysis of variance. NS: not 
significant. 
 
Figure 1: Viability of cancer cells treated with PP-13 or paclitaxel. 
A. A549, 4T1 mRFP-H2B (4T1-RFP), and HeLa mEGFP-α-tubulin mRFP-H2B (HeLa-
EGFP/RFP) were cultured in two-dimensions (2D) or in spheroids, and treated for 72 h with 
increasing concentrations of PP-13 (left) or paclitaxel (right), and the cell viability was 
assessed. Data represent the mean ± SD from three independent experiments, each performed 
in triplicate. B. Representative images of treated spheroids are shown. Bars: 100 µm. 
 
Figure 2: Effects of PP-13 on cancer cell spheroids. 
HeLa mEGFP-D-tubulin mRFP-H2B (HeLa-EGFP/RFP) spheroids were treated with vehicle 
(control), 200 nmol.L-1 PP-13, or 15 nmol.L-1 paclitaxel for 24 h (A-D) or for 72 h (E-F). 
A549 spheroids were treated for 24 h with vehicle (control) or 10 µmol.L-1 PP-13 (C-D). 4T1 
mRFP-H2B (4T1-RFP) spheroids were treated for 24 h with vehicle (control) or 200 nmol.L-1 
PP-13 (D). A. Representative confocal microscopy images of microtubules (α-tubulin-EGFP) 
and phosphorylated histone H3 (H3P, a marker of late G2/M cell cycle phase) 
immunodetection in spheroid sections treated with vehicle (control) or PP-13. In purple: H3P, 
in green: α-tubulin, in red: H2B-RFP, in blue: Hoechst-stained nuclei. The green and blue 
arrows indicate multipolar mitotic spindles and miscongressed chromosomes, respectively. 
Scale bars: 50 µm (20x magnification) and 10 µm (63x magnification). B. Representative 
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confocal microscopy images of H3P analyzed by immunofluorescence on spheroids sections 
treated with vehicle (control), or paclitaxel. In pink: H3P, in blue: Hoechst-stained nuclei. 
Scale bars: 50 µm. C. The percentage of H3P was calculated as the number of H3P-positive 
cells in control (n = 7, HeLa-EGFP/RFP; n=11, A549), PP-13 (n = 13, HeLa-EGFP/RFP; 
n=11, A549), or paclitaxel (n = 9, HeLa-EGFP/RFP) spheroids, with two or three sections per 
spheroid. Data are expressed as the mean ± SD. *** p < 0.0001 between control and treated 
conditions; Mann-Whitney U-test. D. Western blot analysis of H3P in A549, 4T1-RFP, or 
HeLa-EGFP/RFP pooled spheroids (n = 10 spheroids in each condition). Actin was used as a 
loading control. Values indicate relative H3P/actin ratio. E. Representative confocal 
microscopy images of cleaved caspase-3 immunodetection in spheroid sections. In purple: 
cleaved caspase-3, in green: α-tubulin, in red: H2B-RFP, in blue: Hoechst-stained nuclei. 
Scale bars: 50 µm. F. Quantification of cleaved caspase-3 in spheroids (control, n = 9 
spheroids; PP-13, n = 7 spheroids; with two or three sections per spheroids). Data are 
expressed as the mean ± SD. *** p < 0.0001 between control and treated conditions; Mann-
Whitney U-test.  
 
Figure 3: In vitro effects of PP-13 on angiogenesis.  
HUVECs were treated with vehicle (control) or increasing concentrations of PP-13, as 
indicated, for 6 h. A. Capillary-like tube formation assay: representative images of the 
HUVEC capillary-like tube formation in each condition. Bar: 200 µm. B. Quantification of 
the tube length, the cell-covered area, the number of loops and the number of branching 
points. Data are expressed as the mean ± SD and as the percentages of vehicle condition to 
control the seeding variations between the experiments (n = 5). * p < 0.05; ** p < 0.01; *** p 
< 0.001 between control and treated conditions; Kruskal-Wallis test with Dunn’s multiple 
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comparisons post hoc test. C. HUVEC cell viability was assessed. Data represent the mean ± 
SD (n ≥ 3). 
 
Figure 4: In vitro effects of PP-13 on cancer cell migration and invasion.  
A-B. Wound-healing assay in A549, HeLa, and 4T1-rvLuc2 cells treated with vehicle 
(control) or increasing concentrations of PP-13 or paclitaxel for 12 h. A. Representative 
images from wound-healing assay experiment at 0 h and 12 h. Cells were treated with vehicle 
(control), 1 µmol.L-1 (A549 and HeLa) or 0.5 µmol.L-1 (4T1-rvLuc2) PP-13, 20 nmol.L-1 
(HeLa) or 50 nmol.L-1 (A549) or 200 nmol.L-1 (4T1-rvLuc2) paclitaxel. The white lane 
delineates the edges of the wound. B. Relative wound density over time in cells treated as 
indicated. The relative wound density at 0 h is arbitrarily set to 0%. Data are expressed as the 
mean ± SD. Experiments were performed at least five times in triplicate. * p < 0.05; ** p < 
0.01; *** p < 0.001 compared to control or treated conditions as indicated; Friedman test with 
Dunn’s multiple comparisons post hoc test. C-D. Matrigel invasion assay of A549, 4T1-
rvLuc2 and HeLa cells treated treated with vehicle (control), 200 nmol.L-1 (4T1-rvLuc2) or 
500 nmol.L-1 (A549, HeLa) PP-13, or 20 nmol.L-1 (HeLa), 40 nmol.L-1 (A549), or 150 
nmol.L-1 (4T1-rvLuc2) paclitaxel for 24 h. C. Representative images from methylen-blue 
stained cells treated with vehicle (control), PP-13, or paclitaxel. The red squares show the 
quantified cells. D. Quantification of invasion of cells treated with vehicle (control), PP-13, or 
paclitaxel. Cells were counted in ten fields per condition and in three independent 
experiments. Data are expressed as the mean ± SD and as the percentages of vehicle condition 
to control variations between the experiments. * p < 0.05; ** p < 0.01  between control and 
treated conditions; Mann-Whitney U-test. 
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Figure 5: Effects of PP-13 in vivo.  
A. Schematic representation of the in ovo assay principle. A549 cells were engrafted onto 
chick embryo chorioallantoic membranes (CAMs) at E9, were randomized into three groups, 
and treatments with 0.5% DMSO (control, n = 18), 50 µmol.L-1 paclitaxel (positive control of 
tumor growth inhibition, n = 17), or 0.13 µmol.L-1 PP-13 (low dose, n = 18) were 
administered every other day for 10 days. B. Tumors were excised and weighted at the end of 
the treatments. The histogram represents the effect of treatments on A549 tumor weight 
(means ± SEM, n = 16). *** p < 0.001 compared to control; Kruskal-Wallis test. C. The 
presence of A549 cells in the lower CAM at the end of the experiment was evaluated by 
qPCR in ten random embryos per group. The histogram represents the effect of treatments on 
A549 metastases in the lower CAM (means ± SEM, n = 10). The relative amount of 
metastases in the lower CAM in the control group is arbitrarily set to one to control 
interindividual variations. *** p < 0.001 compared to control; Kruskal-Wallis test. 
D. Schematic representation of orthotopic breast tumors and metastatic growth and of the 
treatment plan. The mice were inoculated with 4T1-rvLuc2 cells and randomized into four 
groups of eight mice. Vehicle (control), 0.5 mg.kg-1 paclitaxel, or 0.5 or 1 mg.kg-1 PP-13 were 
administered intraperitoneally three times a week. Thoracic bioluminescence imaging was 
performed once a week for five weeks. After three weeks, the primary tumors were resected. 
E. Primary tumor volume. Data represent the mean ± SEM in each group (n = 8). *** p < 
0.001 compared to control group; two-way ANOVA with Bonferroni post hoc test. F. 
Histogram shows the CD31 positive staining quantification on frozen 4T1-tumor sections, 
expressed as the mean ± SD. The CD31 levels were determined after counting positive 
stained blood vessel area as described in methods, in three sections per tumor and in three 
tumors per group. 
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Figure 6: Effects of PP-13 on thoracic metastases in orthotopic breast tumor model. 
Mice with 4T1-rvLuc2 tumors were treated with vehicle (control), paclitaxel 0.5 mg.kg-1, or 
PP-13 (0.5 and 1 mg.kg-1), 3 times a week (see Fig. 5D). A. In vivo bioluminescence images 
of the thoracic metastases (ventral view) in one representative mouse per group at day twenty-
eight. B. Overtime quantification of in vivo bioluminescence signal in thoracic areas over the 
duration of the experiment (ventral and dorsal views). Data are expressed as the mean ± SEM 
(n = 8). * p < 0.05; **** p < 0.0001 compared to control or to paclitaxel-treated groups; two-
way ANOVA with Bonferroni post hoc test. C. Ex vivo bioluminescence images of lungs at 
the end of the experiment (day 35). (n = 8, except in paclitaxel-treated group, n = 7). D. Ex 
vivo bioluminescence signal in each lung at the end of the experiment (day 35). Bars: mean 
bioluminescence signal (n = 8, except in paclitaxel-treated group, n = 7). Number indicates 
the reduction (%) in mean bioluminescence signal in 1 mg.kg-1 PP-13-treated group, 
compared to control group.  
 
Figure 7: Effects of PP-13 on lymph node metastases. 
Axillary and brachial lymph nodes were collected at the end of the experiment (day thirty-
five) in 4T1-rvLuc2 mice treated as indicated. A. Ex vivo bioluminescence images of lymph 
nodes. RA, right axillary lymph node; LA, left axillary lymph node; RB, right brachial lymph 
node; LB, left brachial lymph node. Each line shows the lymph nodes of one mouse (n = 8, 
except in paclitaxel-treated group, n = 7). Numbers indicates the invaded lymph nodes and 
their percentages in each group. B. Ex vivo bioluminescence signal in each lymph node. Bars: 
median bioluminescence signal (n = 32 lymph nodes/group, 8 mice/group except in 
paclitaxel-treated group: 7 mice, 28 lymph nodes). * p < 0.05; *** p < 0.001; **** p < 0.0001 
compared to control or treated groups; Kruskal-Wallis with Dunn’s multiple comparisons post 
hoc test. ns, not significant. 
Table 1: Sensitivity of cancer cell lines to PP-13 and paclitaxel 
Cell lines and condition 
PP-13 
IC50 [nmol.L-1] 
Paclitaxel 
IC50 [nmol.L-1] 
HeLa 2D 120 ± 10.0 4.0 ± 3.5 
HeLa-EGFP/RFP 
2D 
Spheroids 
75 ± 7.1 
185 ± 49.5 
2.8 ± 0.4 
17 ± 0.6 
A549 
2D 
Spheroids 
120 ± 40 
> 10,000 
9 ± 4.9 
> 500 
4T1-RFP 
2D 
Spheroids 
66.5 ± 2.1 
200 ± 5.8 
35 ± 2.1 
17.5 ± 3.5 
4T1-rvLuc2 2D 69.3 ± 9.0 45 ± 3.0 
 
The drug concentrations required to inhibit cell growth by 50% (IC50) at 72h in HeLa cells, HeLa 
mEGFP-α-tubulin and mRFP-H2B cells (HeLa-EGFP/RFP), A549 cells, 4T1 mRFP-H2B cells (4T1-
RFP) and 4T1-rvLuc2 cells cultured in 2D-monolayer (2D) or spheroids. Data represent the mean ± 
SD of three independent experiments, each performed in triplicate.   
Table 1
Table 2: PP-13 decreased the number of mice with thoracic and lymph node metastases 
 
Treatments 
Mice with thoracic metastases 
(day 14) 
Mice with invaded lymph nodes 
(day 35) 
Number % Number % 
Control 6/8 75 6/8 75 
Paclitaxel 0.5 mg.kg-1 3/8 37.5 5/7 71 
PP-13 0.5 mg.kg-1 5/8 62.5 4/8 50 
PP-13 1 mg.kg-1 4/8 50 1/8 13 
 
Mice with 4T1-rvLuc2 tumors were treated with vehicle (control), paclitaxel 0.5 mg.kg-1, or 
PP-13 (0.5 and 1 mg.kg-1) (see Fig. 5D). Number and percentages of mice with thoracic 
metastases at day 14, and with invaded axillary and brachial lymph nodes at day 35 are shown 
in each group. 
Table 2
Table 3: Mice body-weight 
 
Treatments Mice body-weight at day 28 (%) 
Mice body-weight at day 35 
(%) 
Control 118.75 ± 2.56              115.75 ± 3.57 
Paclitaxel 0.5 mg.kg-1 119.38 ± 1.41              111.29 ± 1.85 
PP-13 0.5 mg.kg-1 113.25 ± 0.86              108.25 ± 3.75 * 
PP-13 1 mg.kg-1 116.13 ± 1.84              116.13 ± 1.72 
 
Mice with 4T1-rvLuc2 tumors were treated with vehicle (control), paclitaxel 0.5 mg.kg-1, or 
PP-13 (0.5 and 1 mg.kg-1) (see Fig. 5D). Mice body-weight is expressed as mean ± SEM 
(n=8, except in paclitaxel-treated group at day 35, n=7), and as percentage of initial body-
weight (day 0). * p <0.05; two-way ANOVA with Bonferroni post-test (day 35 compared to 
day 28). 
Table 3
Table 4: Biochemical analyses of mice 
Plasma biochemistry 
Control                     
(n=6) 
Mean ± SD 
paclitaxel 0.5 mg.kg-1 
(n=6)  
Mean ± SD 
PP-13 1 mg.kg-1       
(n=6)  
Mean ± SD 
Potassium (mEq/L) 6.3 ± 0.8 6.6 ± 0.9 5.8 ± 0.8 
Chloride (mEq/L) 113.2 ± 1.8 110.3 ± 3.4 113.0 ± 1.7 
Calcium (mg/dL) 9.7 ± 0.3 9.6 ± 0.1 9.7 ± 0.4 
Phosphorus (mg/dL) 8.2 ± 1.9 5.4 ± 0.2 * 6.5 ± 0.7 
Glucose (g/l) 2.1 ± 0.4 1.6 ± 0.1 * 2.1 ± 0.3 
Aspartate amino-transferase (UI/L) 201.5 ± 48.2 188.5 ± 56.4 205.7 ± 34.7 
Alanine amino-transferase (UI/L) 33.3 ± 11.3 48.5 ± 10.4 38.0 ± 12.2 
Alkaline phosphatase (UI/L) 52.5 ± 12.3 50.2 ± 9.3 58.5 ± 15.2 
Total bilirubin (mg/dL) 0.2 ± 0.1 0.2 ± 0.2 0.2 ± 0.1 
Total proteins (g/L) 42.0 ± 2.1 43.7 ± 1.9 43.7 ± 2.2 
Albumin (g/L) 23.0 ± 1.5 23.8 ± 2.1 24.5 ± 2.3 
Globulins (g/dL) 1.9 ± 0.2 2.0 ± 0.2 1.9 ± 0.1 
Cholesterol (g/l) 0.7 ± 0.1 0.7 ± 0.1 0.8 ± 0.1 
Triglycerides (g/l) 0.5 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 
Creatinine (mg/l) 9.7 ± 3.4 2.3 ± 0.5 * 4.0 ± 3.9 
Blood Urea Nitrogen (g/l) 0.2 ± 0.02 0.2 ± 0.04 0.1 ± 0.02 * 
 
Plasma biochemical values of mice after control, paclitaxel or PP-13 treatments were 
assessed. Data represent the mean ± SD of 6 mice per group. Data were analyzed using Mann-
Whitney U-test. * Significant as compared to control group. 
Table 4
Table 5: Hematological and bone marrows analyses of mice 
 Control 
(n=8) 
paclitaxel 0.5 mg/kg 
(n=8) 
PP-13 1 mg/kg 
(n=8) 
Mean ± SD Mean ± SD p value Mean ± SD p value 
He
ma
tol
og
ica
l a
na
lys
es 
Red blood cells (RBC) (T/L) 8.2 ± 0.6 7.2 ± 1.0 NS 7.6 ± 0.5 NS 
Haemoglobin (g/dL) 13.7 ± 1.0 12.4 ± 1.7 NS 13.2 ± 0.7 NS 
Haematocrit (%) 40.8 ± 3.3 35.5 ± 4.6 NS 38.1 ± 2.2 NS 
Mean corpuscular hemoglobin 
concentration (MCHC) (g/dL) 33.6 ± 0.5 35.0 ± 0.7 p < 0.01 34.5 ± 0.5 NS 
Mean Corpuscular 
Hemoglobin (MCH) (pg) 16.8 ± 0.4 17.2 ± 0.3 NS 17.3 ± 0.3 NS 
Mean corpuscular volume 
(MCV) (µM3) 50.0 ± 1.2 49.2 ± 1.3 NS 50.3 ± 1.3 NS 
Red cell distribution index 
(RDI) (%) 15.0 ± 1.0 14.9 ± 0.8 NS 14. 6 ± 0.9 NS 
White blood cells 
(WBC) (G/L) 18.3 ± 3.5 11.8 ± 4.0 p < 0.05 17.0 ± 2.9 NS 
lymphocytes (% of WBC) 50.1 ± 8.2 39.1 ± 16.9 NS 47.5 ± 6.4 NS 
Monocytes (% of WBC) 23.9 ± 4.9 26.0 ± 6.6 NS 21.1 ± 1.2 NS 
Granular cells (% of WBC) 26.0 ± 4.0 35.0 ± 11.8 NS 31.1 ± 6.9 NS 
He
ma
tol
og
ica
l a
na
lys
es 
of 
th
e b
on
e m
ar
ro
w 
Cell abundance 
in the bone marrow#  2.4 ± 0.9 3.1 ± 0.4 NS 2.9 ± 0.7 NS 
Megakaryocytes 16.0 ± 6.5 28.7 ± 12.5 NS 18.0 ± 11.0 NS 
Granular line (%) 74.9 ± 9.0 63.4 ± 13.0 NS 65.3 ± 11.1 NS 
Erythroblastic line (%) 14.3 ± 9.6 22.1 ± 14.4 NS 28.6 ± 9.2 NS 
Lymphocytes (%) 6.1 ± 4.1 8.4 ± 3.4 NS 5.2 ± 3.6 NS 
Monocytes (%) 4.8 ± 2.7 6.1 ± 3.9 NS 2.8 ± 2.2 NS 
 
Complete blood count and white blood cells count and evaluation of the global cell abundance 
and megakaryocyte and leukocyte counts in the bone marrow, from mice treated with control, 
paclitaxel, or PP-13. Data represent the mean ± SD of 8 mice per group. # from score 1 (low 
abundance) to score 4 (high abundance). Data were analyzed using one-way analysis of 
variance. NS: not significant.  
Table 5
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